 Confidential  Page 1 of 69 
 
 
 
SICAS -2  Version 3.0  Date 03.27.15   
PROTOCOL NUMBER  U01 -BCH -01 
School Inner -City Asthma I ntervention Study : 
 
VERSION 3.0 / VERSION DATE : 03/27/201 5 
IND#  [n/a]  
Study Sponsor(s):   The National Institute of Allergy and Infectious Diseases (NIAID)  
    
NIAID Funding Mechanism:  U01 AI110397  NCT 02291302  
Study Drug Manufacturer /Provider :  [n/a] 
PROTOCOL  CHAIR - WANDA 
PHIPATANAKUL , MD, MS 
 
Professor of Pediatrics  
[LOCATION_011] Children’s Hospi[INVESTIGATOR_307]  
[ADDRESS_1273186]  
[LOCATION_011], MA [ZIP_CODE]  
Phone:  [PHONE_18794]  
Fax: [PHONE_18795]  
Email:  
wanda.phipatanakul@childrens . 
harvard.edu  
 NIAID  MEDICAL  OFFICER /MONITOR -  
PETER GERGEN , MD, MPH  
Division of Allergy, Immunology, and 
Transplantation – NIAID /NIH  
[ADDRESS_1273187]  
Bethesda, MD [ZIP_CODE] -9828 , [LOCATION_003]  
Phone:  [PHONE_17986]  
Fax:  [PHONE_1895]  
E-mail:  [EMAIL_2091]   BIOSTATISTICIAN - BRENT COULL , PHD 
Professor of Biostatistics  
Harvard School of Public Health  
[ADDRESS_1273188]  
[LOCATION_011], MA [ZIP_CODE]  
Phone: [PHONE_18796]  
Fax: [PHONE_18797]  
E-mail: [EMAIL_17274]  
 
  NIAID   NURSE CONSULTANT /PROJECT  
MANAGER -KATHERINE THOMPSON  
Division of Allergy, Immunology, and 
Transplantation – NIAID/NIH  
[PO_BOX]  
Lecanto, FL [ZIP_CODE] , [LOCATION_003]  
Phone:  [PHONE_18798]  
E-mail:  [EMAIL_17275]  REGULATORY  OFFICER  – Ling Li Ph.D  
OFFICE OF  REGULATORY AFFAIRS  
Division of Allergy, Immunology, 
and Transplantation – NIAID/NIH  
[ADDRESS_1273189]  
Bethesda, MD [ZIP_CODE] -9828 , [LOCATION_003]  
Phone: ([PHONE_18799]  
Fax: (301) 480 -1537   
E-mail: lil16 @niaid.nih.gov  
 
 
 Confidential  Page 2 of 69 
 
 
 
SICAS -2  Version 3.0  Date 03.27.15   
 
Protocol Synopsis  
Title  School Inne r-City Asthma Intervention Study  
Short Title  SICAS -2 
Clinical Phase  II 
Number of Sites  1 
IND Sponsor/Number   n/a 
Intervention(s)  A. Classroom Air Filter Purifier, School Integrated Pest 
Management  
 B. Endpoints:  Asthma Symptoms,  health care utilization, rescue 
medication use,  lung function  
Study Objectives  The primary  objective  is to determine  the efficacy  of this 
environmental  intervention  to improve  asthma  outcomes.  
Study Design  The study  is a randomized, double -blind, placebo controlled, 
parallel Classroom Air Filter Intervention  and a single -blind, 
controlled  parallel  trial of a school -wide (with targeting of 
participant classrooms)  mouse -targe ted integrat ed pest  
management  (IPM)  intervention.  
Primary Endpoint(s)  The primary  outcome  measure  is maxim um days  of symptoms/  2 
weeks. Max imum  days of asthma  symptoms  will be assessed  by 
[CONTACT_906966], ICAS, 
and ICAC consortiums  and studies1-4. The primary endpoint is the  
longitudinal vector of symptom -days at each of the five visits  
(baseline and follow up)  for each subject.    
Secondary Endpoint(s)  Second ary outcomes  include:  (1) school absences, ( 2) health care 
utilization, 3) Composite Asthma Severity Index adapted from the 
Inner -City Asthma Consortium5, and incorporates day symptoms,  
short -acting  beta  agonist  use,  nights  symptoms, and exacerbations 
(defined as systemic steroids for asthma) and lung function.  Core 
outcomes come from  the recent Asthma Outcomes Workshop6 
These  data  will be obtained from  questionnaires, and lung function 

 Confidential  Page 3 of 69 
 
 
 
SICAS -2  Version 3.0  Date 03.27.15  (i.e. FEV1/FVC, FEV [ADDRESS_1273190],  FEF 25% -75%) with  Koko  spi[INVESTIGATOR_906897] (Primary and 
Secondary)  
Accrual Objective  250 
Study Duration  52 months  total duration (accrual  40 months  + follow -up period  12 
months  
Treatment Description   There  will be four  parallel  groups randomized in a multi -level, 
factorial fashion:  The student’s primary CLASSROOM will be 
randomized to Air Filters versus Sham Control.  Simultaneously, 
the student’s  SCHOOL will be randomized to receive intense  IPM 
INTERVENTION  (extermination  and sealing  of sealing  of holes and 
cracks surrounding the classroom/cafeteria),  education, reservoir 
clean ing versus control.   
Inclusion Criteria  Subject and/or parent guardian must be able to understa nd and 
provide informed consent  
Males  and females  who  will be in grades K -8 (age 4 -15 at 
randomization)  during the subsequent academic schoo l year after 
spring screening  
 
Attend one of the schools that study team have permission to 
obtain classroom/school environmental samples for the 
subsequent academic school year.  
 
Have  no plans  to move s chools  within  the upcoming  [ADDRESS_1273191]  one of 
the following:  
 One asthma -related  unschedul ed visit to an emergency 
department  (ED),  clinic  or urgent  care facility  in the 
previous  12 months  
 One asthma -related  overnight  hospi[INVESTIGATOR_906898]  12 months  
 One or more  bursts  of oral or injectable cortic osteroids  in 
the previous  12 months   
 Wheezing symptoms in the past 12 months  
 On Daily controller medications for asthma  
 
 Confidential  Page 4 of 69 
 
 
 
SICAS -2  Version 3.0  Date 03.27.15  Inclusion /exclusion  criteria modeled from the NIAI D funded Inner -
City Asthma Studies )1-4 
Exclusion Criteria  for Individual  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Exclusion Criteria for School  Individuals  who meet any of these criteria are not eligible 
for enrollment as study participants :  
Inability or unwillingness of a participant to give written informed  
consent or comply with study protocol  in the judgment of the PI  
 
[INVESTIGATOR_906899],  other  than asthma,  that requires  daily medication  
 
Cardiovascular  disease  that requires  daily  medication,  excluding 
hypertension  
 
Taking  a beta-blocker  
 
Currently  receiving escalation (has not reached maintenance) of 
Immunotherapy  (allergy shots)  
 
Switching to a school where staff  are not doing environmental 
sampling for that year.  
 
Past or current medical problems or findings from physical 
examination or laboratory testing that are not listed above, which, 
in the opi[INVESTIGATOR_871], may pose additional risks from 
participation in the study, may interfere with the participant’s 
ability to comply with study requirements or th at may impact the 
quality or interpretation of the data obtained from the study . 
 
 
Unable  to access  areas of school  necessary  to conduct  extermination  
 
School  in extensive  state  of disrepair /damage  as determined  by 
[CONTACT_121364]/PI  [INVESTIGATOR_906900] 5 of 69 
 
 
 
SICAS -2  Version 3.0  Date 03.27.15   
 
Table of Contents  
Glossary of Abbreviations  ................................ ................................ ................................ ................................ .......................  9 
1. Background and Rationale  ................................ ................................ ................................ ................................ ............  10 
1.1. Background and Scientific Rationale  ................................ ................................ ................................ .....................  10 
1.2. Preclinical Experience: n/a This is an environmental intervention ................................ ................................ .......  14 
1.3. Clinical Studies for Intervention  ................................ ................................ ................................ ............................  14 
Summary of Other Relevant School -Based Interve ntion Studies:  ................................ ................................ ................  15 
2. Study Hypotheses/Objectives  ................................ ................................ ................................ ................................ .......  16 
2.1. Hypotheses ................................ ................................ ................................ ................................ ............................  16 
2.2. Primary Objective(s)  ................................ ................................ ................................ ................................ ..............  16 
To determine whether a school/classroom -based environmental intervention ( classroom  High Efficiency Particulate Air 
(HEPA) filter/purifying units and school  integrated pest management) will:  ................................ ................................ ...... 16 
2.3. Secondary Objective(s)  ................................ ................................ ................................ ................................ .........  16 
To explore whether sensitization or other asthma phenotypes defined at baseline modify which pathways or networks 
of genes undergo intervention -related change s in methylation or gene expression that, in turn, are associated with 
improvement in asthma outcomes . ................................ ................................ ................................ ................................ .. 16 
3. Study Design  ................................ ................................ ................................ ................................ ................................ .. 17 
3.1. Description of Study Design  ................................ ................................ ................................ ................................ .. 17 
3.2. Primary Endpoint  ................................ ................................ ................................ ................................ ..................  18 
3.3. Secondary Endpoint  ................................ ................................ ................................ ................................ ..............  20 
3.4. Exploratory Enpoint(s)  ................................ ................................ ................................ ................................ ..........  21 
3.5. Stratificatio n, Randomization, and Blinding/Masking  ................................ ................................ ..........................  22 
4. Selection of Participants and Clinical Sites/Laboratories ................................ ................................ ..............................  23 
4.1. Rationale for Study Population  ................................ ................................ ................................ .............................  23 
4.2. Inclusion Criteria  ................................ ................................ ................................ ................................ ...................  23 
4.3. Exclusion Criteria for Participant  ................................ ................................ ................................ ..........................  24 
4.4. Selection of Clinical Sites/Labs  ................................ ................................ ................................ ..............................  [ADDRESS_1273192] or Intervention cited in Medical Literature and/or those based on the 
Investigators’ experience  ................................ ................................ ................................ ................................ ..................  25 
5.3. Risks of Other Protocol Specified Medications  ................................ ................................ ................................ ..... 25 
5.4. Risks of Study Procedures  ................................ ................................ ................................ ................................ ..... 26 
5.5. Potential Benefits  ................................ ................................ ................................ ................................ ..................  27 
6. Intervention  ................................ ................................ ................................ ................................ ................................ .. 27 
6.1.1.  Inter vention #1 ................................ ................................ ................................ ................................ ..............  27 
[IP_ADDRESS].  Formulation, Packaging, and Labeling  ................................ ................................ ................................ ...... 28 
[IP_ADDRESS].  Dosage, Preparation, and Administration  ................................ ................................ ................................ . 28 
6.1.2.  Intervention #2 ................................ ................................ ................................ ................................ ..................  28 
6.1.2. 1. Formulation, Packaging, and Labeling  ................................ ................................ ................................ ...... 28 
6.2. Assessment of Participant Compliance with Investigational Agent  ................................ ................................ ..... 28 
6.3. Toxicity Prevention and Management  ................................ ................................ ................................ ..................  28 
6.4. Premature Discontinuation of Investigational Agent  ................................ ................................ ...........................  29 
7. Other Medications  ................................ ................................ ................................ ................................ ........................  29 
7.1. Concomitant Medications  ................................ ................................ ................................ ................................ ..... 29 
7.2. Prophylactic Medications  ................................ ................................ ................................ ................................ ...... 29 
7.3. Prohibited Medications  ................................ ................................ ................................ ................................ .........  29 
7.4. Rescue Medications  ................................ ................................ ................................ ................................ ..............  29 
8. Study Procedures  ................................ ................................ ................................ ................................ ..........................  29 
8.1. Enrollment  ................................ ................................ ................................ ................................ .............................  29 
Screening Visit  ................................ ................................ ................................ ................................ ................................ ... 29 
8.2 HEPA Air Filter Accountability  ................................ ................................ ................................ ...............................  34 
9. Mechanistic Assays  ................................ ................................ ................................ ................................ .......................  37 
10. Biospecimen Storage ................................ ................................ ................................ ................................ .................  38 
11. Criteria for Participant and Study Completion and Premature Study Termination ................................ ..................  38 
11.1.  Participant Completion  ................................ ................................ ................................ ................................ ..... 38 
11.2.  Participant Stoppi[INVESTIGATOR_73821]  ................................ ................................ ........................  39 
11.3.  Participant Replacement  ................................ ................................ ................................ ................................ ... 39 
11.4.  Follow -up after Early Study Withdrawal  ................................ ................................ ................................ ...........  39 
 Confidential  Page 7 of 69 
 
 
 
SICAS -2  Version 3.0  Date 03.27.15  12. Overview  ................................ ................................ ................................ ................................ ................................ ... 39 
12.1 Definitions  ................................ ................................ ................................ ................................ ................................ . 40 
12.1.2 Adverse Event (AE)  ................................ ................................ ................................ ................................ .............  40 
N/A ................................ ................................ ................................ ................................ ................................ ................  41 
12.2.2 Unexpected Adverse Event  ................................ ................................ ................................ ................................  41 
12.2.3 Serious Adverse Event (SAE)  ................................ ................................ .................  Error! Bookmark not defined.  
12.2 Grading and Attribution of Adverse Events  ................................ ................................ . Error! Bookmark not defined.  
12.2.1 Grading Criteria  ................................ ................................ ................................ ................................ ..................  41 
12.2.2 Attribution Definitions  ................................ ................................ ................................ ................................ .......  42 
12.4 Collection and Recording of Adverse Events  ................................ ................................ ................................ ............  42 
12.4.1 Collection Period  ................................ ................................ ................................ ................................ ................  42 
12.4.2 Collecting Adverse Events  ................................ ................................ ................................ ................................ .. 43 
12.4.3 Recording Adverse Events  ................................ ................................ ................................ ................................ .. 43 
12.5 Reporting of Serious Adverse Events and Adverse Events  ................................ ................................ .......................  43 
12.5.1 Reporting of Serious Adverse Events to Sponsor (DAIT/NIAID)  ................................ ................................ .........  [ADDRESS_1273193](DDSMB) Review  ................................ ................................ ........................  44 
13. Statistical Considerations and Analytical Plan  ................................ ................................ ................................ ..........  45 
13.1  Overview  ................................ ................................ ................................ ................................ ...............................  45 
13.2  Outcomes (Described in 1.1 -1.3) ................................ ................................ ................................ ..........................  45 
Primary Outcome(s)  ................................ ................................ ................................ ................................ ..........................  45 
Maintenanc e of Trial Treatment Randomization Codes  ................................ ................................ ................................ ... 45 
13.4  Analysis Plan  ................................ ................................ ................................ ................................ ..........................  46 
13.4.1  Analysis Populations.  ................................ ................................ ................................ ................................ .... 46 
13.4.2  Primary Analysis of Primary Endpoint(s)  ................................ ................................ ................................ .......  46 
 Confidential  Page 8 of 69 
 
 
 
SICAS -2  Version 3.0  Date 03.27.15  13.4.3  Supportive Analyses of the Primary Outcome  ................................ ................................ ..............................  48 
13.4.4  Analyses of Secondary and Other Endpoint(s)/Outcome(s)  ................................ ................................ .........  48 
13.4.5  Analyses of Exploratory Endpoint(s)  ................................ ................................ ................................ .............  51 
13.4.6  Descriptive Analyses  ................................ ................................ ................................ ................................ ..... 52 
Descriptive Analyses  ................................ ................................ ................................ ................................ .....................  52 
13.5  Interim Analyses  (Not Applicable: Environmental Intervention - NOT a medication, high risk intervention)  ..... 52 
13.6  Statistical Hypothe ses ................................ ................................ ................................ ................................ ...........  52 
Aim 1: To determine the effectiveness of a school/classroom based environmental intervention [ Classroom  particle air 
filter/purifying units and school -wide integrated pest management (IPM)] to:  ................................ ................................ .. 52 
13.7  Sample Size Considerations Samp le Size Estimates:  ................................ ................................ .............................  [ADDRESS_1273194]  
FDA Food and Drug Administration  
FeNO  Fractional Exhaled Nitric Oxide  
FEF 25 -75%  Forced expi[INVESTIGATOR_66753] 25 -75% of vital capacity  
FEV [ADDRESS_1273195]  
ISM Independent Safety Monitor  
MAAIT  Mouse Allergen Asthma Intervention Trial  
MOP  Manual of Procedures  
n/a Not Applicable  
NHLBI  National Heart Lung Blood Institute  
NIH National Institute s of Health  
NIAID  National Institute of Allergy and Infectious Disease s 
NO [ADDRESS_1273196]  
PI [Site] Principal Investigator  
[INVESTIGATOR_906901] -City Asthma Study - observational study  
 Confidential  Page 10 of 69 
 
 
 
SICAS -2  Version 3.0  Date 03.27.15  SICAS -1 School  Inner -City Asthma Study -observational study  
SICAS -2 School Inner -City Asthma Intervention Study – proposed clinical trial  
SOP Standard Operating Procedure  
1. Background and Rationale   
1.1. Background  and Scientific Rationale  
A) Impact and Significance   Asthma affects 12 -15% of children in urban [LOCATION_002], accounts for over 14 million 
missed school days per year7, and costs billions of dollars in health care utilization despi[INVESTIGATOR_906902]8. 
  
B) Scientific Background and Rationale   
Elementary school children spend 7 to 12 hours a day  in school, (primarily in one classroom), and school is nearly every 
child’s “required occupation” and source of multiple environmental exposures.  The School Inner -City Asthma Study -1 
(SICAS -1) (RO1 AI 073964, Phipatanakul) is the first obsetrvational Ame rican  study to comprehensively evaluate the role 
of urban exposures in school, classroom and home environments and asthma morbidity9, 10.  SICAS -[ADDRESS_1273197] demonstrated that 
targeted interventions (including air filter units) are effective in decreasing asthma morbidity1, 15-17.  Using established 
integrated pest management measures,  we are currently conducting an NIAID -funded home intervention clinical trial (AI 
083238) to evaluate mouse -targeted IPM effects on asthma morbidity18. SICAS [ADDRESS_1273198] demonstrated that we can effectively decrease classroom -specific toxic exposures during the 
academic school year by 7 5% to 90% utilizing cleverly engineered, effective, and quiet classroom -suitable  High Efficiency  
Particulate Air (HEPA) air filters.   
 
C) Innovation and Advancement of the Field:  Our next step is to apply successful school/community -based strategies to 
determine whether a school/classroom intervention  will efficiently and effectively improve asthma morbidity by 
[CONTACT_906967].  This is an unprecedented, high impact oppo rtunity to test whether we can efficiently 
benefit a community of children in the school environment as opposed to individuals in single homes. Our goal  is to 
determine the efficacy of a two -pronged intervention using classroom  particle air filter units an d school -wide targeted 
IPM/cleaning in reducing asthma morbidity in urban school children. Furthermore, we aim to link molecular mechanisms 
induced by [CONTACT_906968] -modifying effect s on 
the epi[INVESTIGATOR_307999]/transcriptom e. 
 
D) Knowledge and Unmet Need Fulfilled from this Study to Reduce the Impact of this Public Health Concern  and 
Sustainability  
 
Our study is the  first ever comprehensive school -based environment intervention trial of HEPA filtration and IPM to 
improve asthma. Our engineers have unique skills and experience which they applied to development, tailoring and 
successful pi[INVESTIGATOR_906903] (and matched sham filter controls) which we 
have demonstrated to be effective in reducing exposures and acceptable in the classrooms setting. Our established, 
 Confidential  Page [ADDRESS_1273199] particular relevance to long -term public policy and planning for 
disadvantaged urban U.S. schools with similar indoor environment s, where, as we found in  17% of elementary school 
children wake up  at night because of asthma and 15% have missed school or medical care for asthma in the past year.  
Our proposed interventions will likely result in net savings, where implementation costs are offset by [CONTACT_906969] -
days and improved quality of life for children, less health care utilization and less loss of work -days (greater economic 
productivity) for caregivers. Previous indoor environment intervention trials focused on individuals in single homes.  If  
we demonstrate  that reduction  of classroom -specific exposures  leads  to improved asthma  outcomes,  then  our findin gs 
can be translated into efficient and cost -effective strategies to benefit communities of children through improving the 
school environment, where children in America spend t he majority of their day.  
Rationale for Selection of Intervention   
A) Nature of Intervention to be Tested:  
 Classroom Environmental Intervention:  After randomization, active or sham (placebo) HEPA air filters will be 
placed in the primary home classroom, where elementary  students  spend the majority of their day .  The students, 
staff, and investigators will be blinded to active versus sham. The Air Filters:  AP103A model (Woongjin Coway Co., 
Ltd; Oreck Air Instinct™ 200, Oreck Direct, LLC) captures particles down to 0.1 micron in size and has a maximum 
clean air delivery rate (CADR) of 160 ft3/min (CFM) for dust. The filt er is designed for rooms up to 4 00 sq. ft., 4 filters 
worked well in our Pi[INVESTIGATOR_906904] -received in classroom/school setting.   School Interv ention: The Integrated  Pest  
Management  (IPM)  School  will receive  an IPM strategy (exterminat ion with  rodenticide,  traps, and sealing  of holes  
and cracks),  air filters,  clean ing reservoirs,  and educa tion regardi ng pest  control  measures.  The intervention  
procedures  will be those  that were  used  in a pi[INVESTIGATOR_906905] ,18 and the ICAS Pongracic Study15, and the 
current NIAID funded MAAIT Study ( AI 083238). The school -specific IPM will focus on surrounding areas that feed 
into the classroom and harbor infestation by [CONTACT_906970] (i.e. cafeteria).  This is modeled after the home 
interventions  that work by [CONTACT_906971]’s bedroom, surrounding areas, and the kitchen.  The home -based 
strategies have been proven as effective and cost -effective strategies for reducing pertinent allergen exposure and 
improving health outcomes in homes1.   Our school -based strategies will focus on the child’s primary classroom, 
surrounding areas, and the cafeteria.   Unlike home intervention strategies, where it is impossible to blind, the 
School IPM strategies may also be single blinded, because the students attend school during the day, and the IPM 
will be conducted after hours when the students are home.  Therefore, staff will know which sc hool is randomized 
to IPM but  the students will be blinded.  
B) Stage of Intervention  Phase III  Environmental Intervention with Extensive Home -based C linical experience that will be 
described in section 1.4    
C) M echanism of action of the Intervention  Reducing  classroom/school  environmental exposure  to particulate matter 
and its associated allergen and mold particles . Targeted integrated pest management to further reduce mouse allergen.   
 Confidential  Page 12 of 69 
 
 
 
SICAS -2  Version 3.0  Date 03.27.15   D) Rationale for the Intervention  Targets to Address the Overall Study O bjective (Described in S ection 2 )  
RATIONALE FOR CLINICAL TRIAL INTERVENTION TARGETS: Mouse, Mold and Particle Pollution  
 
1.1.  Supporting Data (Clinical Aim 1):Overview of SICAS -1:  SICAS -1, our school -based inner -city observational study, 
was designed to assess the relation of classroom/school environment allergen and mold exposure to asthma morbidity, 
adjusting for home exposure. It is the most comprehensive study of its kind ever performed in the [LOCATION_002]4, 9, 19-24. 
Every spring, screening surveys in English or Spanish were distributed to all  students at 8 -10 elementary schools. Of 
7032 school children screened, 22% had a history of asthma, which for most children was active and involved health care 
utilization: 15% of the [ADDRESS_1273200] 12 months, and 17% had 
night time asthma symptoms.  
From the 700 -1000 surveys collected each spring, children with asthma were recruited for extensive summer 
baseline phenotypic assessments, including allergy and lung function testing. Every year approximat ely 75 -100 students 
were enrolled from 8 -10 unique schools. School/classroom visits were conducted twice during the academic school year, 
approximately [ADDRESS_1273201] measures1 (Table 1 ) of 
maximum number of symptoms per 2 week period, school absences for asthma, caregiver and health care utilization 
data were collected 3, 6, 9, and 12 months after summer baseline assessments. During the academic school year we also 
measured follow up lu ng function and fractional exhaled NO (FeNO). We assessed associations of school, classroom and 
home specific exposure data to child health outcomes obtained during the academic school year. Seventy -percent of 
enrolled children had at least one positive sk in test. While specific sensitization to mouse was associated with slightly 
higher symptom counts ( Fig. 2 ), the association of mouse allergen level with maximum symptom counts /2 weeks did not 
differ for those with any sensitization vs no sensitization. Ou r findings reported below (Sections 1.1.a, b, and c ) support 
our hypothesis that our interventions will benefit all the asthmatic children.  
1.1.a. S ICAS -1 Mouse Allergen , Mold Allergen and Particle Pollution Classroom/School Exposures:   We measured 
exposur es in all 36 schools and 241 classrooms of participating students  (N=351) . All schools and 99% of classrooms had 
detectable mouse allergen. Compared to participants’ home levels9, 10, their classroom levels of mouse allergen were 
consistently higher20. Levels were markedly above levels shown to incre ase asthma morbidity in other studies14 and 
comparable  to those seen in occupational research facilities that house/breed mice26.  School cat and dog allergen  levels 
were variable9 and not at levels previously shown to worsen symptoms27.  While there was very little dust mite or 
cockroach allergen, we measured significant dust and airborne mold levels in the schools21.  As well as reducing mouse 
exposures, our SICAS -2 intervention (IPM/cleaning and HEPA air filters) will decrease molds and other allergen or irritant 
compone nts of particles (see Sections 1.2 and 1.3  for preliminary data demonstrating intervention efficacy).  
1.1.b. Classroom MOUSE Exposur e and Asthma Symptoms : SICAS -1 enabled us to identify the independent  role of 
classroom mouse allergen exposure in exacerbation of asthma symptoms, adjusting for potential confounders: home 
environmental tobacco smoke, endotoxin,  household income, gender, age, race, body mass index28, perceived stress29 
cockroach and home mouse exposure. Upon updating analyses since the last submission to include our  full asthma 
cohort, we observe that higher mouse allergen levels in classrooms were associated with higher asthma symptoms in the 
school year for all study participants , and these associations were not modified by [CONTACT_906972]. Overall a 
10-fold increase in mouse allergen levels was associated with 45% more symptom days (95% CI: 9% to 91%, p=0.01) per [ADDRESS_1273202] symptoms than are specifically sensitized, suggesting 
non-allergic effects of mouse allergen or mouse -associated particle exposures31.   
 
 Confidential  Page 13 of 69 
 
 
 
SICAS -2  Version 3.0  Date 03.27.15  Classroom MOLD Exposure and Multiple As thma Outcomes:   For clinically relevant taxa (e.g., Penicillium/ Aspergillus, 
Alternaria)32, our classroom mold levels were also higher than those identified in home -based inner -city studies linking 
mold to increased asthma symptoms in children33.  Previously we reported associations of mold with symptoms only for 
mold -sensitized students.12 Subsequent preliminary analyses for the full SICAS -1 cohort show that regardless of 
sensitization status, higher classroom air Alternaria was linked to more missed sleep due to as thma, changed caregiver 
plans [OR=1.96(1.27, 3.02); p=0.002 for a SD increase in Alternaria level], and a higher composite outcome score (more 
dyspnea, nocturnal wheeze, limited activity, rescue medication) [OR=1.73(1.19, 2.52)].  There is ample evidence that 
molds in home/school environments can worsen symptoms via not only allergic, but also non -allergic, irritant 
mechanisms.33-35 
 
Classroom Pollut ion Exposur e and Asthma Symptoms :  Pollution has been shown to worsen asthma in urban children36.  
SICAS -1 was not funded for air pollution assessment but outside funds enabled us to measure classroom -specific air 
pollutants over 1 week periods [integrated NO 2, black carbon (BC), PM 2.5; continuous PM 2.5] in a subset of classrooms.  In 
SICAS -1 students, we demonstrated a exposure -response relationship between increasing concentrations of indoor NO 2 
(ppb) and more asthma symptom -days, (adjusted relative rate (RRadj)=1.05 per unit increase in NO 2 levels (95% CI=  
1.02, 1.08), p=0.002)13.   NO 2 is likely a marker for local traffic and regional pollution infiltrating indoors,37 given the 
absence of indoor school sources for this pollutant. We found similar exposure -response relationsh ips of BC and PM 2.5 
with increased symptoms;power was limited by [CONTACT_906973].  
 
1.2. Pi[INVESTIGATOR_906906]:  We acknowledge that there is a paucity of data relating school -specific interve ntions 
and asthma/allergic symptoms.  We conducted a pi[INVESTIGATOR_906907] (AP1008BH and AP1008CH model, 
Woongjin Coway Co., Ltd; Oreck Air Instinct™ 200, Oreck Direct, LLC) in two neighboring classrooms of approximately 
1000 ft2 in the normal classroom setting (control and intervention).  Environmental sampling was conducted at baseline, 
during a two -week intervention and immediately after the intervention to compare exposure levels between the control 
and intervention classrooms  at baseline, during, and post intervention.  Particle Reduction: Our pi[INVESTIGATOR_581283] a 75% reduction in PM 2.5 from the HEPA particle filter/purifiers after adjusting for natural ambient 
particles in control classrooms. Using the same study design , in another busy building, when windows were closed or 
minimally opened we demonstrated an 87-97% reduction in particles  and a 74% reduction when windows were opened 
2.2 cm.   
 
 
Allergen/Mold Reduction:  Classroom HEPA air filters alone reduced airborne mo use allergen by 75%  compared to 
control classrooms but did not reduce settled dust levels (which we plan to reduce with IPM).   We found similar effects 
of HEPA filters in reducing classroom cat and dog allergen levels, which were, as previously documented , low to begin 
with, and therefore, likely of limited clinical significance38.  We also demonstrated that classroom HEPA filters reduced 
mold levels (measured by [CONTACT_906974] -1) by 79%  in one day.  Mold levels rose back up to basel ine 
when the air filter/purifiers were turned off.  
 
1.3. Pi[INVESTIGATOR_906908]:  With donated resources, we conducted Integrated Pest Management (IPM) targeting mouse 
allergen in the school, utilizing simi lar methods conducted in homes18 and the NIAID home IP M study  (AI 083238).  IPM 
included inspection, trappi[INVESTIGATOR_906909], and exclusion (door sweeps and filled heating pi[INVESTIGATOR_906910]).  Within a couple months of school -wide  IPM (focused on cafeteria/classroom, targeting 
surro unding reservoirs), we were able to effectively r educe classroom mouse allergen levels in settled dust by 75%.  
 
 Confidential  Page [ADDRESS_1273203] shown that we can reduce these exposures in 
our real world urban school settings.  Addressing reviewer conce rns that only children with specific sensitization to mouse 
or mold would benefit from SICAS -2 interventions  --reduction of classroom airborne particles (including particle -
associated mouse and mold allergens as well as pollution) and pest management of mo use and other associated 
exposures -- our data suggest that all symptomatic asthmatic school children will benefit.   
 
E) Advantages of I ntervention  to be Tested:   SICAS -2 will be a factorial design with  the classroom randomized  double -
blind, placebo contro lled to Air Filter/purifier and  school being randomized in a parallel fashion to an intervention  of 
IPM/Education /Clean ing v ersus Control School.  This allows the advantage of understanding the classroom specific 
benefits of the air filter/purifier and  school wide (focused on classroom /cafeteria, and surrounding supporting areas ) 
effects  of the IPM intervention. Factorial design s have been validated and established39, [ADDRESS_1273204]:  Schools are equivalent to occupational settings: we have shown that exposures  (especially to 
mouse) can be at occupational levels. Approaches to reduce exposure in the work place are relevant for improvement of 
asthma in large populations of school children. Our study is the  first ever comprehensive school -based environment 
interve ntion trial of HEPA filtration and IPM to improve asthma. Our engineers have unique skills and experience which 
they applied to development, tailoring and successful pi[INVESTIGATOR_906911] (and 
matched sham filter c ontrols) which we have demonstrated to be effective in reducing exposures and acceptable in the 
classrooms setting. Our established, successful community relationships over the past decade  make us uniquely 
positioned to give back to the community who, aft er participation in SICAS -1, [ADDRESS_1273205] prevalent and 
costly chronic diseases of childhood, in a large community of vulnerable symptomatic urban children.  
 
1.2. Preclinical Experience : n/a This is an environmental intervention  
1.3. Clinical Studies  for Intervention  
Home Allergen Exposure, Sensi tization, and Asthma Morbidity: Allergen exposure in home environments is an 
important trigger in 80% to 90% of children with asthma41, 42.  It is well established from multiple cohorts, particularly 
NIAID funded National Cooperative Inner - City Asthma Study  (NCICAS)  and Inner -City Asthma Study/Consortium  
(ICAS/ICAC)  that certain unique inner -city allergenic exposures  in home environments such as cockroach43-[ADDRESS_1273206] increased asthma symptoms and morbidity when exposed to that specifi c 
allergen in the home.   Mold, such as Alternaria, Aspergillus, Cladosporium, and Penicillium , may be an important 
respi[INVESTIGATOR_906912]33, 54-56 .   The Inner -City Asth ma Study  showed that particulate matter from outdoor pollution was 
 Confidential  Page 15 of 69 
 
 
 
SICAS -2  Version 3.0  Date 03.27.15  highly prevalent in homes57, and that higher outdoor concentrations of NO 2 (from auto emissions) and indoor particulate 
pollutants were associated with asthma morbidity in urban children with asthma36.  High indoor particulate -matter was 
associated with decreased lung function, greater respi[INVESTIGATOR_1856], more frequent use of rescue medications 58, 59, 
and evidence of inflammation as measured by [CONTACT_906975]59. 
Home Based Allergen/Mold Abatement Interven tion Studies: There has been significant attention to the potential role 
of intervention measures in inner -city homes to reduce allergen exposure (particularly  mouse,  dust mite , and cockroach) 
and asthma morbidity in sensitized individuals60-64.  Review of these data concluded that interventions to reduce these 
allergen levels should be routine in the management of allergic asthma and have shown benefit in reducing asthma 
symptoms and m orbidity, particularly in those sensitized to the specific allergen60, 65-67,68-71.  In the Inner -City Asthma 
Study  (ICAS) , a recent comprehensive home intervention targeted at allergens to which the child was sensitized was 
foun d to be cost -effective72 and helpful in decreasing asthma symptoms1.  ICAS also demonstrated children sensitized to 
mouse allergen who had targeted mouse allergen intervention resulting in 50% reduction in home exposure 
dem onstrated reduced asthma morbidity15.  
In the ICAS, a substudy in 40 children that decreased mouse allergen by 50% regardless of baseline levels, were 
associated with decreased morbidity15.    In only 18  homes (12 intervention 6 controls), decreasing mo use allergen by 
75% reduced symptom days by 1/week, but was just not powered for significant effects18.   
Recent publications from this work did determine that mold exposure was associated with symptoms and that simple 
home -based interventions that have worked in NCICAS and ICAS were beneficial for these children.    In a Hurricane 
Katrina study, simple intervention of education and providing caretakers with HEPA filters showed reductions of mold 
counts by 50% and reduction of symptoms73.    
We are currently conducting an NIAID funded intervention trial in [LOCATION_011] and Baltimore  (AI 083238) using an established 
targeted method to decrease mouse allergen in homes of children with asthma18.  While not a randomized controlled 
trial, we have evidence from our partners i n the Children’s Hospi[INVESTIGATOR_906913] d Pest Management (IPM) referrals improved health outcomes and was highly cost -effective in 
reducing hospi[INVESTIGATOR_906914]74, suggesting interventions to reduce exposures are important in 
reducing asthma morbidity.  
Air Pollution Intervention in Homes : Regardless of baseline levels, a New Zealand home inte rvention  by [CONTACT_57971] g gas 
flues  to reduce NO 2 from gas stoves  (geometric mean 7.3 mcg/m3 versus 10.9 mcg/m3 in controls, P<0.01), resulted in 
significant reduction in asthma symptoms75. 
Summary of  Other  Relevant School -Based Intervention Studies:  
There is a paucity of comprehensive data on school/classroom based environmental intervention studies and its effects 
on asthma morbidity.  One Swedish study showed that levels of airborne cat allergen can be reduced by [CONTACT_906976] [ADDRESS_1273207] decreased self -reported asthma symptoms, but these studies did not influence actual cat allergen levels 78. 
 Confidential  Page 16 of 69 
 
 
 
SICAS -2  Version 3.0  Date 03.27.15  Mold Intervention in Schools : Pi[INVESTIGATOR_906915] a mold intervention in only two  (one 
intervention one control) Finnish schools34 with 50% reduction in mold levels.  In a comparison of only two schools (one 
with intervention and one without), there were significant differences in symptoms by [CONTACT_906977] 
50%34.    
NO 2 air pollution Intervention in Schools: In one Australian school study an intervention replacing unflued gas heaters 
with electric heaters among 199 students (45 intervention and 73 controls) attending  18 schools effectively reduced NO 2 
(Intervention mean (standard deviation) 15 ppb (6.6) and Control 47 ppb (26.8) and improved asthma symptoms  as 
measured by d ifficulty breathing during the day (Relative Risk [RR] = 0.41; 95% CI: 0.07, 0.98) and night (RR  = 0.32; 95% 
CI: 0.14, 0.69), chest tightness during the day (RR = 0.45; 95% CI: 0.25, 0.81), and daytime asthma attacks (RR = 0.39; 
95% CI: 0.17, 0.93)79.  Most schools in the [LOCATION_002] no longer have active kitchens with stoves so the indoor source 
of NO 2 as seen in the Australian study is not applicable in Am erica.   
2. Study Hypotheses/ Objectives   
2.1. Hypotheses   
Our central hypothesis is that  reducing classroom/school exposure to particles and their associated allergens 
(particularly mouse/mold) will decrease asthma morbidity in students with asthma.   In School Inner -City Asthma 
Intervention Study -2 (SICAS -2) we plan to test our central hypothesis in an intervention study  of 300 elementary school -
aged children with asthma from multiple classrooms in 40  inner -city elementary schools.  
2.2. Primary Objective(s)  
To deter mine whether a school/classroom -based environmental intervention ( classroom  High Efficiency Particulate Air 
(HEPA) filter/purifying units and school  integrated pest management) will:  
(a)  Reduce asthma symptoms (primary outcome as used in other NIAID inne r-city asthma studies1, 3); and  
(b)  Reduce medication use, health care utilization, and improve lung function (secondary outcomes).  
 
 
2.3. Secondary Objective(s)  
 To explore whether sensitization or other asthma phenotypes defined at baseline modify which pathways or networks 
of genes undergo intervention -related changes in methylation or gene expression that, in turn, are associated with 
improvement i n asthma outcomes . 
 
Mechanistic Objective:  
Hypothesis -  Growing evidence suggests that asthma phenotypes are sustained by [CONTACT_906978][INVESTIGATOR_307997]80  . 
To test the hypothesis that effects of school/classroom -based environmental interventions on symptoms/other 
measures of asthma control occur through changes in gene methylation or expression in pathways (and secondarily, in 
genes) relevant to airway function and asthma.  Within pathways or networks of genes (pre -specified or discovered in 
 Confidential  Page 17 of 69 
 
 
 
SICAS -2  Version 3.0  Date 03.27.15  unsupervised analyses) we will (a) determine how our interventions influence changes in airway cell methylation or gene 
expression and (b) evaluate how our intervention -associated changes in methylation and gene expression influence 
asthma outcomes.  Finally, using mediation anal ysis, we will (c) estimate how much of the intervention effects on asthma 
symptoms occur through methylation/expression changes86, 87. 
3. Stud y Design  
3.1. Description of Study Design  
SICAS -2 is a factorial, randomized, placebo controlled, parallel group phase II clinical trial designed to assess the efficacy 
of a classroom (Air Filter) and , randomized,  controlled,  parallel  group  school (IPM)  environment al interventi on in 
improvi ng asthma  control  in children with  asthma.   SICAS -2 is a single -center  environme ntal intervention  study . Three  
hundred  children  attending one of the Schools in the  metropolitan area  (SBMA) (total of 40 schools) from September 
thru June in grades K to 8th  (generally ages 4 -15) will  be randomized to one of the  four groups  (75 per group) : 
 (1) IPM School/Classroom Air Filter  
 (2) IPM School/Classroom Sham (Placebo) Air Filter  
(3) Control School/ Classroom Air Filter  and 
 (4) Control School/Classroom Sham (Placebo) Air Filter .  
Each  randomized  particip ant will be followed  for a total  of about 12 months,  approximately  6-12 weeks  prior  to 
randomization  and 10 months  following  randomization.  
   
 
 
 
 
 
 
 
 
 
 
 Confidential  Page 18 of 69 
 
 
 
SICAS -2  Version 3.0  Date 03.27.15  Figure 1 SICAS -2 Annual Schema  
fall winter spring
Season
Clinical 
Trial
*Classroom HEPA filter vsSham Control
School -wide IPM vsschool -wide ControlRandomization*
Mechanistic
CoreNasal cell collection
for methylation &
expression analysisNasal cell collection
for methylation &
expression analysisPFT/ FeNO
School/Home 
ExposurePFT/ FeNO
School/Home 
ExposureIntervention* 
Ends
summer spring
Baseline 
Survey
PFTs/ FeNOIntervention
StartsScreening
Recruitment
75 students/year, 10 schools
300 students, 40 schools, 4 yearsBaseline 
School
ExposureSchool 
ends
Follow -up surveys every 2 monthsSchool
startssummer
 
 
 
 
 
 
 
 
 
 
*Arms of SICAS -2 Study  
Cohort  A - ARM 1  75 SCHOOL: IPM INTERVENTION  
CLASSROOM: AIR FILTER  
Cohort  B  - ARM 2  75 SCHOOL: IPM INTERVENTION  
CLASSROOM:  SHAM (PLACEBO) AIR FILTER  
Cohort C  - ARM 3  75 SCHOOL: CONTROL  
CLASSROOM: AIR FILTER  
Cohort D  - ARM 4  75 SCHOOL: CONTROL  
CLASSROOM: SHAM (PLACEBO) AIR FILTER  
 
3.2. Primary Endpoint    Annual recruitment schema depi[INVESTIGATOR_1230].   Schools randomized to IPM/Targeted Cleaning Reservoirs Parallel Design.  Within 
schools, classrooms randomized to air purifiers or sham purifiers in double blind, placebo controlled fashion.  Target annual  
recruitment is 75 students enrolled per year fro m 8-10 unique schools. Target study enrollment Year 1 -4  is 300 students 
from 40 uniqu e schools.     Year 5, complete follow -up, data analysis.  * Primary efficacy is ascertained at baseline  and the 
follow -up phone surveys conducted every [ADDRESS_1273208] ran domization (Schedule of events/procedures, Table 2, page 34)  
 Confidential  Page [ADDRESS_1273209] value among the following three variables: number 
of days with wheezing, tightness in the chest, or cough; number of nights with disturbed sleep as a result of asthma; and 
number of da ys on which the child had to slow down or discontinue play activities because of asthma.  The primary 
endpoint is the longitudinal vector of symptom -days at each of the visits for each subject ascertained at baseline and 
every two months  follow up during th e school year after randomization.  W e have proposed to include visit number, 
which will does not serve as a confounder but will remove any seasonal variation in symptoms exhibited independent of 
intervention groups.  This is the main advantage of using th e vector of multiple visit -specific symptom outcomes as the 
outcome, rather than the average of the values over the post -randomization period  and allows us to control for 
covariates.    Max imum  asthma symptom days  over  two weeks  will be compared  between the  4 groups: (1)  IPM 
School/Classroom Air Filter (2) IPM School/Classroom Sham (Placebo) Air Filter, (3) Control School/ Classroom Air Filter  
and (4) Control School/Classroom Sham (Placebo) Air Filter .  This is the same primary outcome used in the other NIAI D 
funded Inner -City Asthma Consortium Studies1, 3. 
 
The disease pattern that we anticipate (and have seen in SICAS -1) will be representative of that of most inner -city urban 
asthmatic children. Many have frequent nighttime awakenings with asthma symptoms, disrupted activities, and 
frequent use of rescue med ication. Their disease takes its economic toll through loss of caregiver work days, and child 
absences or increased health care utilization that does not necessarily involve hospi[INVESTIGATOR_906916].  Our primary composite outcome  “maximu m symptom days” was used and validated as the primary outcome  in 
the Inner -City Asthma3, 14, 33, [ADDRESS_1273210] -benefit analyses by [CONTACT_512072] -
City Asthma trial1, 72, 88.  
 
Table  1: Primary and Secondary Clinical Outcomes1, 5, 72, [ADDRESS_1273211], or cough  and/or  
2. Nights with disturbed sleep as a 
result of asthma and/or  
3. Days on which the child had to 
slow down or discontinue play 
activities because of asthma  
Secondary   Clinical Outcomes  Primary Indices  
School Absences  Number of school days missed 
because of asthma/ 2 weeks  
  
  
Health Care Utilization  Total asthma -related unscheduled 
visits (UVs) defined as sum of 
unscheduled clinic visits and 
emergency department visits, and 
asthma -related overnight 
hospi[INVESTIGATOR_602] /school year*  
Composite Asthma Severity 
Index5  Day symptoms and albuterol use, 
night symptoms and albuterol use, 
controller treatment, lung function, 
 Confidential  Page 20 of 69 
 
 
 
SICAS -2  Version 3.0  Date 03.27.15   
 
 
 
 
3.3. Secondary Endpoint  
Secondary outcomes specified in Table 1  will be standardized according to the recent Asthma Outcomes Workshop 
guidelines5, 6. They incl ude school absences, Health Care Utilization; the Composite Asthma Severity Index  PFT’s  and 
degree of exposure reduction . As demonstrated in our Cost Effectiveness Analysis Plan, a number of these outcomes can 
be used in estimating costs of the asthma morb idity and cost savings of the intervention.  
 
 
Pulmonary  function:  
FEV 1, 
FEV 1/FVC  
FEF 25% -75%  
percent  change in FEV 1 after  short -acting  bronchodilator  
 
 
Mechanistic Endpoints:   
To explore whether sensitization or other asthma phenotypes defined at baseline modify which pathways or networks 
of genes undergo intervention -related changes in methylation or gene expression that, in turn, are associated with 
improvement in asthma outcomes.  
DNA/RNA Methylation/Transcriptomic Biomarkers. DNA methylation  and RNA  gene  expression  will be measured as 
described below. Within pathways or networks of genes (pre -specified or discovered in unsupervised analyses) we will 
(a) determine how our interventions influence changes in airway cell methylation or gene expression and (b)  evaluate 
how our intervention -associated changes in methylation and gene expression influence asthma outcomes.  Finally, using 
mediation analysis, we will (c) estimate how much of the intervention effects on asthma symptoms occurs through 
methylation/expre ssion changes86, 87 
Thus these measures can be considered to be i ntermediate outcomes, but the changes in these measures between 
baseline and near the end of the intervention are being considered both as outcomes of the interventions, as predictors 
of the clinical outcomes (e.g., symptoms/2 -week period) and finally, as mediators of the relationship of the interventions 
to the clinical responses.  and exacerbations (defined as 
systemic steroids for asthma  )* 
Pulmonary Function (PFT)  FEV 1; FEV 1/FVC*  
[Secondary indices :  (a) FEF 25-75.  
(b) Bronchodllator responsiveness 
(% change in FEV [ADDRESS_1273212] albuterol)]  
Degree of Exposure Reduction  Health Outcomes (Primary and 
Secondary)  
* Standardized  core asthma outcomes  from  Asthma Outcomes  Workshop5, 6  
**Health care use post randomization  
 Confidential  Page 21 of 69 
 
 
 
SICAS -2  Version 3.0  Date 03.27.15  Precious specimens beyond our scope to analyze with funding from this proposal will be saved to provide opportunities 
for future testing of follow -up hypotheses.  
Mechanistic endpoint is m agnitude of changes in cell gene methylation or expression in pathways (and secondarily, in 
genes) relevant to airway function and asthma to determine if the effects of school/classroom -based environmental 
interventions on symptoms/other measu res of asthma control occur through these changes. This will be done by 
[CONTACT_906979] (pre -specified or discovered in unsupervised analyses) we will (a) 
determine how our interventions influence changes in  airway cell met hylation or gene expression and (b) evaluate how 
our intervention -associated changes in methylation and gene expression influence asthma outcomes.  Finally, using 
mediation analysis, we will (c) estimate how much of the intervention effects on asthma sympto ms occur through 
methylation/expression changes  
3.4. Exploratory Enpoint(s)  
1. Days  of rescue  medication  use/2  weeks;  
2. Days  of cough  without  a cold/2  weeks;  
3. Days  of exercise -induced asthma  symptoms/2  weeks;  
4. Nocturnal  symptoms/2  weeks.  
5. Days  of slowed  activity/[ADDRESS_1273213]  
8. Pulmonary  inflammatio n, assessed  by [CONTACT_906980] (FeNO)  
The followi ng exploratory research  questions  will also be addressed : 
(1) In the Intervention  Group,  does  the degree  of exposure  reduction  modify  the effect  of the intervention  on asthma  
outcomes?  
 
(2) Is there a multi -level effect in relation to School, Home, Class  Effect  on outcomes ? 
 
(3) In the Intervention  group,  does  the presence  of other  indoor allergen  sensitiviti es and  exposures  modify  the effect  of 
the intervention  on asthma  outcomes?  
 
4) Does  the degree  of sensitization  to mouse  or mold  (skin test size of allergen specific IgE level)  mod ify the effect  of the 
intervention?  
Any of the above  sensitization  and exposure  criteria  
Other  cut points  will also be determined  a priori  and interacti ons will  also be tested  using  exposure  as a continuo us 
variable based on the literature of clinically relevant exposure and sensitization levels.  
 
5) Does obesity  defined as Body Mass Index for age/percentiles  modify these outcomes? This variable will be analyzed 
and adjusted for in models.  
 
6) Does perceived stress  defined as standardized perceived stress score29 modify these outcomes?  This variable will be 
analyzed and adjusted for in models.  
7) Does sleep (habits ,quality)  affect any of these outcomes?    
Validated comprehensive sleep questions and sleep diary  will be collected.  
 Sleep quality assessed with  wrist actigraphs  (sleep monitors)  which are worn for 5 -7 days  while sleepi[INVESTIGATOR_007] .  
Sleep quality assessed with sound level meter which will be placed in the home for 5 -7 days.  
 Confidential  Page 22 of 69 
 
 
 
SICAS -2  Version 3.0  Date 03.27.15  Sleep Disordered Breathing  will be assessed with the nasal oxygen cannula monitor and pulse oximeter.  
These variable will be analyzed and adjusted for in models  
 
8) Does pulse  oximetry/  CO-Oximetry affect any of these outcomes? This variable will be analyzed and adjusted for in 
models  
 
9) Are there any urinary biomarkers that predict outcomes? (i.e. metabolomics,  proteomics,  pesticides,  urinary 
chemicals (  BP-3, BPA, Butylparaben, Ethylp araben, Methylparaben, Propylparaben, Triclosan, 2,4 -dichlorophenol and 
2,5-dichlorophenol, ispoprotenes, pesticides, benzenes, leukotrienes , and creatinine) , that could effect outcomes  
 
10) Are there any environmental metagenome, microbiome markers that could affect  outcomes?  
 
11) Are there any fungal, microbiome, bacterial markers that could affect  or predict outcomes? (shot gun sequencing, 
ergosterol)  
 
12) Would any food allergen exposu res in the environment effect outcomes (i.e. peanut, milk, egg proteins)?  
 
13) Does the intervention improve symptoms of other students in the classroom (i.e. non -allergic, nasal, irritant, other)?  
 
14) Are there any other immune biomarkers which could fur ther our understanding of mechanisms behind the response 
to our intervention such as  pro-inflammatory cytokines such as IL -6, IL-33, leptin, basophils, TNF α, IFN -γ and other 
cytokines,  
 
15) Are there gender differences that could modify our outcomes incl uding  serum gender specific hormones (i.e. 
E2,DHEAS,testosterone, SHBG, Progesterone)  
 
16) Could certain nasal viruses, microbial organisms, and bacteria affect these outcomes?  
 
17)  Do Patient Reported Outcomes Measurement Information System (PROMIS) variables that measure patient –
reported health status for physical, mental, and social well –being.affect our outcomes  and are they reproducible in 
other cohorts of asthma and other chronic diseases?  
 
18.  Does the intervention prove to be cost -effective? ( i.e. if it decreases missed school days and parent/caregiver 
missed days of work and improve quality of life in comparison to the cost of the intervention is it cost -effective?)?  
 
19.  Could any markers of ventilation, CO2, temperature and humidity affect outcomes?  
 
3.5. Stratification, Randomization, and Blinding /Masking  
Rand omization:  Particip ants will be randomized  within  three  weeks  of the screening school  visit in a 1:1 ratio  using a 
statistical software  package  to generate  random numbers.  The randomization  sche me will be developed  by [CONTACT_906981].  
Participants  at each  site will be randomized  indepe ndently  of the other  sites,  and random  blocks  of 4 to 6 will be used to 
maintain  similar  enrollment  into the two study  groups  at each  site. There  will be no stratif ication.   
 Confidential  Page 23 of 69 
 
 
 
SICAS -2  Version 3.0  Date 03.27.15  Masking:   Although  it may  be possible  to attempt  to mask  some study  staff  by [CONTACT_906982] 1-[ADDRESS_1273214] with the study participants will service 
and change the air filters every 3 months at the school after school hours, maintaining participants, PI, and study staff 
blind ing. 
All laborato ry studies  (allergen  ELISAs,  allerge n-specific  IgE levels ,  endotoxin  levels,  PM 2.5, Black Carbon  level s, NO 2 
levels, and mold)  will be performed  in central ized laborator ies in batch es to minimize  variability  of the  assay.  
4. Selection of Participants and Clinical Sites/Laboratories  
4.1. Rationale for Study Population  
Health disparities urban school aged children is particularly high in regards to  asthma  and its  associated morbidity , 
costing billions of dollars in health care utilization.  Recent NIH/ NIAID efforts have put significant resources in identifying  
remediable causes , particularly in the home environment.[ADDRESS_1273215] of that time is spent in one classroom. It is nearly every child’s required occupation al 
environment .  Our observational School Inner -City Asthma Study (SICAS -1) demonstr ated the importance of the school 
environment in inner -city environments among elementary students.  Therefore, focusing our population in elementary 
school age inner -city children makes this an ideal population for this study.   Our proposed age/grade leve ls are a time 
where children spend the majority of their day in a primary classroom, and prior to further effect modifying changes 
that may change during puberty.   
 
We are simply building on our established protocol and infrastructure developed during SIC AS-[ADDRESS_1273216] whether we can efficiently benefit a community of children in the school environment as opposed 
to indi viduals in single homes .  
4.2. Inclusion Criteria  
Individuals who meet all of the following criteria are eligible for en rollment as study participants:   
1. Subject and/or parent guardian must be able to understa nd and provide informed consent  
2. Males  and females  who  are grades K -8 (age 4 -15) during the subsequent academic school year after spring 
screening .  
 Confidential  Page [ADDRESS_1273217] permission to obtain classroom/school environmental samples for 
the subsequent academic school year.  
4. Have  no plan s to move schools  within  the upcoming  [ADDRESS_1273218]  one of the following:  
 Wheezing symptoms in the past 12 months  
 On Daily controller medications for asthma  
 One asthma -related  unschedul ed visit to an emergency department  (ED),  clinic  or urgent  care facility  in the 
previous  12 months   
 One asthma -related  overnight  hospi[INVESTIGATOR_305476]  12 months   
 One or more  bursts  of oral or injectable  cortic osteroids  in the previous  12 months  
 (criteria modeled from the NIAI D funded Inner -City Asthma Consortium  inclusion /exclusion  criteria  and SICAS ) 1-4 
4.3. Exclusion Criteria  for Participant  
Individuals  who meet any of these criteria are not eligible for enrollment as study participants :  
1. Inability or unwillingness of a participant to give written informed consent or comply with study protocol  
Coordinator/PI  [INVESTIGATOR_137929]   
2. Lung  disease,  other  than asthma,  that requires  daily medication  
3. Inability to do lung function testing  
4. Cardiovascular  disease  that requires  daily  medication,  excluding hypertension  
5. Taking  a beta-blocker  
6. Currently  receiving escalation (has not reached maintenance) of  Immunotherapy  (allergy  shots)  
7. Switching to a school where staff are not doing environmental sampling for that year.  
 
8.  Current, diagnosed, mental illness or current, diagnosed or self -reported drug or alcohol abuse that, in the opi[INVESTIGATOR_8574], would interfere with the participant’s ability to  comply with study requirements  
Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, 
which, in the opi[INVESTIGATOR_871], may pose additional risks from pa rticipation in the study, may interfere with 
the participant’s ability to comply with study requirements or that may impact the quality or interpretation of t he data 
obtained from the study . 
Exclusion Criteria for School  
1. Unable  to access  areas of school  necessary  to conduct  extermination  
2. School  in extensive  state  of disrepair /damage  as determined  by [CONTACT_305702]  
3. Centralized  Air Filtration or Purifying System ( although feasible to account for this, rare in  schools)  
 
 Confidential  Page 25 of 69 
 
 
 
SICAS -2  Version 3.0  Date 03.27.15  4.4. Selection of Clinical Sites/Labs  
The Children’s Hospi[INVESTIGATOR_906917] (ACRC)  is run by [INVESTIGATOR_124]. Wanda Phipatanakul and was the single 
site that conducted all the clinical visits and recruitment for SICAS -1, and successfully recruited 400 elementary school 
children with the ident ical inclusion/exclusion criteria for SICAS -2.  SICAS -1 entailed identical clinical procedures and a 
more aggressive milestone target than proposed for SICAS -2, ensuring the success of this Intervention protocol.   
 
The CTSU laboratory  is experienced in molecular biology procedures, immunological assays, radioimmunoassays, and 
specialized sample processing of various body fluids. Genetic testing and evaluation is also available as part of the 
Children’s Hospi[INVESTIGATOR_906918] .  As part of Harvard Catalyst, the study has access to all the CLIA approved 
laboratory facilities of Children’s Hospi[INVESTIGATOR_906919]  (HSPH)  Laboratory of Human Epi[INVESTIGATOR_906920] , the Program in Genomics,  the 
Integrated Health Science Facility ,  the Harvard Partners  Microarry Core  and Columbia University  for the nasal 
epi[INVESTIGATOR_18193] /expression mechanistic studies , and the  HSPH  Environmental Chemistry Laboratory  for th e analysis of 
environmental particulate matter and pollutants.  University of Iowa  will provide the analysis of the mold spore sampling 
and allergen/endotoxin analysis of the environmental dust and air samples.  This entire infrastructure and set up has 
already been running in place successfully for SICAS -1.  
5. Known and Potential Risks and Benefits to Participants  
5.1. Risks of Investigational Product or Intervention as cited in Investigator Brochure  or Package Insert  
Not Applicable: Environmental Intervention  
5.2. Risks of Investigational Product or Intervention cited in Medical Literature  and/or those based on the 
Investigators’ experience  
Portable Room  High Efficiency Particulate Air (HEPA) Air Purifier Filters  are commercially available and provide no risk to 
the children as they are used to improve environmental air quality.   
Integrated Pest Management  may involve using caulking agents , traps, sealing plugging of  holes and keep pests out of 
buildings  as directed by [CONTACT_543954].  
Cleaning  will be st andard practices that are to improve the environ ment and as routinely done by [CONTACT_906983] a school 
setting.  We pl an to use non -bleach agents .      Commercially available, non -bleach cleaning agents (e.g. 409®, Fantastik®) 
will be used. The risk of any irr itation or symptoms is very small. The cleaning agents will be used as directed by [CONTACT_906984].  
Commercially available, non -bleach cleaning agents (e.g. 409®, Fantastik®) will be used during the cleaning that occurs 
during the first  IPM visit.  Commercially available foam caulking agents (Pur -fill®) will be used to seal holes and cracks 
during the IPM visits.  Both of these agents contain potential irritants that could cause asthma symptoms.  The risk of 
developi[INVESTIGATOR_906921]. The cleaning agents 
will be used as directed by [CONTACT_87079].   
5.3. Risks of Other Protocol Specified Medications  
 Confidential  Page 26 of 69 
 
 
 
SICAS -2  Version 3.0  Date 03.27.15  Risks of Albuterol: Albuterol is a medicine used routinely to help diagnos e asthma and to treat asthma, and 
serious reactions are rare. The more common side effects are  
 fast heart beat  
 shakiness  
 upset stomach  
 heartburn  
 nervousness  
5.4. Risks of Study Procedures  
 
Skin Testing:  
There is a risk of  
 Feeling of itching where the skin test was done,  
 Red raised bump, like an insect bite, where the skin test was done  
 Rarely wheezing or shortness of breath  
 1 in 10,000 tests results in a reaction such as sneezing, itchy eyes or hives  
 Even more rarely, a re action may occur that may be life -threatening, and in extremely rare cases may 
cause death  
Stoppi[INVESTIGATOR_906922]: If  child is taking antihistamine medication, and stops tak ing it before skin testing,  
child may have more allergy symptoms such as sneezin g, runny nose or stuffy nose.  
 
Blood Draw : Taking blood may cause pain, bleeding, or bruising where the needle is placed.  
 In rare cases, it may result in fainting.  
 There is a small risk of infection.  
 
Spi[INVESTIGATOR_038]  
• Light -headedness during the breathing o ut period.  
• Occasionally minor chest soreness for several days after the testing.  
 
 
Exhaled Nitric Oxide  
• Your child may become lightheaded or dizzy but this is unlikely  
 
Pulse Oximetrry/  
 There are no known risk s  
 
Pulse CO Oximetry  
 There are no known risks  
 
Sleep Monitor   
 The nasal sensor may cause slight discomfort i.e.tickling sensation in the nose).  
 The actigraph worn on the wrist overnight m ay cause slight discomfort.  
 
Saliva  
 There is no known risk associated with spi[INVESTIGATOR_17270] a cup.  
 Confidential  Page 27 of 69 
 
 
 
SICAS -2  Version 3.0  Date 03.27.15   
Buccal brush Collection  
 There is no known risk associated with the collection of buccal cells using small, soft brush  
 
Urine Collection  
 There is no known risk associat ed with providing a urine sample  
 
Nasal swab/blow  
 There is no know n risk with providing a nasal sample  in this manner . 
 
              Skin swab  
•  There is no known risk with providing a skin swab  
 
Nasorption  
• There is no know n risk with providing a nasal fluid sample  in this manner  
 
 
Nasal Epi[INVESTIGATOR_765896]  
  
 Epi[INVESTIGATOR_3940]  
 Nose may feel a bit of tickling in the area or mild irritation . 
 
5.5. Potential Benefits  
Individual participant benefits  : The potenti al benefits  for the study  participant  includes  receiving  an assessment  of 
allergic  sensitiviti es, assessment  of school  environmental exposures,  classroom  air filters,  extermination  and cleaning,  as 
well as education regarding  environment al control  practices.  The study  participants  may  also benefit  from  improved  
asthma  control.  
 Benefits to Society  : The potential  benefits  to others  include  the identification  of a method  to reduce  asthma morbidity  
in students.  This knowle dge could impact  policy  decisio ns regarding environmen tal interventions  to reduce  
school /classroom  exposures  that may  trigger asthma  symptoms.  This information  will directly  impact  the medical  care 
provided  to this patient  population  and could  confi rm the role of a school/classroom based environmental interventions 
that could effectively and efficiently benefit a community of children.  If we demonstrate  that  reduction  of classroom -
specific exposures  leads  to improved asthma  outcomes,  then  our findin gs can be translated into efficient and cost -
effective strategies to benefit communities of children through improving the school environment, wher e children in 
America spend the majority of their day.  
6. Intervention  
6.1.1.  Intervention  #[ADDRESS_1273219]   AP1013A model  High Efficiency Particulate Air (HEPA) Air Purifier Filtration Unit - commercially available 
for use of air filtration in homes, buildings, and classrooms  
 Confidential  Page 28 of 69 
 
 
 
SICAS -2  Version 3.0  Date 03.27.15  [IP_ADDRESS].  Formulation, Packaging, and Labeling  
Four  COWAY  AP1013A  model , room  Air Filters  will be deployed  in each  school randomized  to the IPM Group  (appropriate  
for rooms  up to 170 square feet).  Units  will be depl oyed in the enrolled SICAS -2 student’s  primary classroom. Number of 
Units will be determined by [CONTACT_906985].  The units  are avail able in commercial  pack aging that includes  an 
instruction  manual . The HSPH Intervention Core will do the masking and blinding of the Sham (Placebo) Air Filters and 
the Active Air Filters with a coded randomization for deployment. The study staff and investigators will be blinded to 
whether the A ir Filters are Active or Sham.  For details on commercially available air fi lters,  used commercially  in rooms 
for air filtration,  company website (Ransport,New Jersey or Los Angeles, CA ) 
http://coway -usa.com/product/03_airpurifier.html   
 
[IP_ADDRESS].  Dosage, Preparation, and Administration  
Air filter  units will be stored at each  site accord ing to the manufacturer’s recommendations  and product label .   Air filter 
units  will be checked  for function ality prior  to deploying  in a school.  
6.1.2.  Intervention  #[ADDRESS_1273220] Management /Cleaning  
[IP_ADDRESS].  Formulation, Packaging, and Labeling  
We are modeling methods off of published methods that work in homes , which led to  our  NIAID funded Home based 
study (Mouse Allergen Asthma Intervention Trial  U01AI 083238) , and which utilizes successful strategies  reducing mouse 
allergen in homes.  
In order  to ensure  the provision  of high  quality  IPM services  according  to the  study  protocol,  IPM compan y (Buono Pest)  
that have been trained for the NIAID AI [ADDRESS_1273221]  will 
provide  approximately  3-4 IPM technicians  who  will undergo  training  for the  SICAS -2 IPM protocol  along  with  the IPM 
Company  President/CEO and/or  operations  manager,  which ever is most  appropriate.  
Overvie w: Each  IPM Module  will include  two school  visits.  The first visit of each  module  will be conducted  by a Research  
Assistant  (RA) and an IPM technic ian (IT) from  Buono Pest . The two IPM visits  will be 4±[ADDRESS_1273222]  of two IPM visits  that will be 4±3 weeks 
apart.   The control  group  will receive  one IPM interv ention  visit.  IPM is further described in the study procedures section 
8 after  completion  of the  study.  
6.2. Assessment of Participant Compliance with Investigational Agent  
Not Applicable (Environmental Intervention)  
6.3. Toxicity Prevention and Management  
Not Applicable (Environmental Intervention)  
 Confidential  Page 29 of 69 
 
 
 
SICAS -2  Version 3.0  Date 03.27.15  6.4. Premature Discontinuation of Investigational Agent  
Not Applicable (Environmental Intervention)   
7. Other Medications  
7.1. Concomitant Medications  
7.1.1.  Protocol -mandated  
Not Applicable(Environmental Intervention)  
7.1.2.   Other permitted concomitant medications  
Medications  and/or  procedures  prescribed  by [CONTACT_31823] t’s health  care provider  or initiated  and obtained  by [CONTACT_906986]’s  parent /guardian  are permitted.  
7.2. Prophylactic Medications  
Not Applicable  
7.3. Prohibited Medications  
Taking  a beta-blocker  
Currently  receiving escalation (has not reached maintenance) of Immunotherapy  (allergy  shots)  
Antihistamines  will be discontinued  for 3-5 days  prior  to the screening  clinic  visit for skin testing.  
7.4. Rescue Medications  
 Not Applicable.  
8. Study Procedures  
Clinical  and Environme ntal Evaluations  will occur  during  five types  of study events: clinic  visits,  telephone  
questionnaires,  school/home  assessment  visits , home assessment visits, and school subject follow -up visit .  
8.1. Enrollment  
We will utilize the same successful recruitment/enrollment strategy that we have been implementing in SICAS 1.  
We will use, a s we have done successfully in SICAS -1, validated screening surveys89( collected un der a screening survey 
protocol)  that were  distributed to [ADDRESS_1273223] averaged 1000 to 1500 surveys returned each spring.  
Potential  study particip ants will be screened  over  the teleph one and those  who  meet study  criter ia and fulfill 
inclusion/exclusion criteria by [CONTACT_906987] a baseline enrollment study  visit in the clinic.  
  
8.[ADDRESS_1273224]  at the  Children’s Hospi[INVESTIGATOR_906917] (ACRC)  in order to confirm eligibility 
and phenotypi[INVESTIGATOR_906923]’ asthma before randomization at the start of the school year. The 
procedures performed will be:  
 Informed Consent : The research study will be explained in lay terms to each potential research participant. The 
participant ’s parent/guardian  will sign an informed consent form and the partic ipant will sign an assent form 
before u ndergoing any study procedures . Once the informed consent  and assent have  been signed, the 
participant is considered enrolled in the study and will be assigned a unique participant number . 
 Questionnaires  - assess clinical characteristics (asthma symptoms, health care utilization, home characteristics);  
 Anthropometric Measurement s: Height, weight and waist will be taken.  
 Oximetry : The saturation of oxygen will be obtained by [CONTACT_906988].  
 CO ox imetry  : The percentage carbon monoxide in the blood will be assessed by [CONTACT_1299] a small device in one of 
the fingers . 
 Skin testing:  Allergy  skin testing  will be performed  to [ADDRESS_1273225]  II device (Lincoln  
Diagnostics, Decatur,  IL). The allerg en extracts  to be used  are: Timothy grass, Penicillium, German Roach, Oak 
tree pollen, Dog, Cat, Mouse  epi[INVESTIGATOR_24603] , Rat  epi[INVESTIGATOR_24603] , Dermatophagoides  farinae , Dermatophagoides 
pteronyss inus Der p, Aspergillus mix, Alternaria tenuis, Cladosporium, Ragweed pollen mix . Skin tests  will be 
performed  according  to standard  procedures90 
 Fractional Exhaled NO (FeNO):  FeNO  is a known  marker  of pulmonary  inflammation  and will provide  a non -
invasive  means  of assessing pulmonary  inflammation .. Measurem ent of exhaled  nitric  oxide will be obtained  prior  
to lung  funct ion testing,  and will  be obta ined accord ing to the American  Thoracic  Socie ty Guidelines91. Exhaled  
nitric  oxide  concentrations  will be meas ured using  an FDA-appr oved (for clinical  use in asthma  management ) 
handheld  device that uses  electr ochemical  technology  to quantify  FeNO  levels (NIOX  Mino /NIOX Vero  System,  
Aerocrine,  Sweden).  . 
 Spi[INVESTIGATOR_906924] : Pre- and post -bronc hodilator  spi[INVESTIGATOR_906925]92. At least  three  reproducible  flow -volume  loops will be  obtained  using  the portable  
Koko  spi[INVESTIGATOR_14007],  after  which  albuterol  will be administered  via nebulizer.  Approximately  10-[ADDRESS_1273226] -bronchodi lator FVC,  FEV1,  FEF25 -
75, and PEF.   
 Nasal swab/blow: This will be obtained by [CONTACT_906989] a nasal sample kit to be 
frozen and save d for future analysis of viral and microbial organisms that could affect clinical response to the 
intervention.  
 Skin swab:   This will be obtained by [CONTACT_906990] a damp swab. This sample will be 
frozen and saved for future analysis of viral and microbial organisms that could affect clinical response to the 
intervention.  
 Nasorption:  This will be obtained by [CONTACT_1299] a small pie ce of absorbent paper in one of the nares of the child’s 
nose and staff will hold that side close for a few seconds. These samples will be stored and may be used for 
future understanding of inflammatory markers linked with asthma or environmental changes  
 Confidential  Page 31 of 69 
 
 
 
SICAS -2  Version 3.0  Date 03.27.15   Nasal brushing (optional):   Only children who have agreed to this procedure We will collect nasal epi[INVESTIGATOR_906926]. The procedure will be done in kids [ADDRESS_1273227] visualization with  a nasal illuminator. This procedure will be done one time before the start of school and 
one time before the child finishes the school year. The procedure will only be done in the hospi[INVESTIGATOR_132265].  The 
collected brush will be submerged in RLT Plus lysis buff er plus b -mercaptoethanol and frozen at -80 degrees C 
until extraction. Samples will be stored at Baccarelli’s Laboratory.  
 Venipunctu re A 35 ml venous  blood  sample  will be obtained  so that the serum can  be used  to measure  total  IgE 
and allergen -speci fic IgE levels. Cell count with differential to obtain eosinophils will also be obtained. The 
leftover serum and plasma will be frozen at Biocore (BCH)for future research use.  
Urine  Collection:  A sample of 25  ml of urine will be collected  and Nic-Alert/cotinine and specific gravity measure 
done.  An aliquot  of urine from  the screening  visit will be  saved for  measurem ent of F-isoprostane, pesticides  and 
other  inflammatory  markers.  Additional aliquots will be saved and frozen  in the biorepository for future use.  
 Saliva : This sample will be used to measure cortisol levels as a marker for stress. Children will chew on parafilm 
paper for up to 15 minutes or until 6 -10ml of saliva are collected. The sample will be aliquoted. They will be sent 
to be frozen and stored  in the biorepository for future use should funding become available.  
 Buccal Swabs(optional):  This sample will be collected to look into DNA/RNA epi[INVESTIGATOR_906927]. We will use a cytology brush (6 brushes) to get the sample from the inside of the 
cheeks and lips. This sample will be frozen and saved in the biorepository for future use should funding become 
available.   
 Sleep monitor (optional):   There are 3 parts of this evaluation.  
a)  Evaluation of sleep disordered breathing : The subject will wear a home sleep testing device that is  
FDA approved to safely monitor sleep in children down to age 2. There are three sensors 1) a pneumatic 
sensor attached to a Velcro belt measures respi[INVESTIGATOR_21266]. 2 ) a nasal cannula records airflow and 
snoring and 3) a pulse oximeter measures pulse and  oxygen saturation. The device will be worn for [ADDRESS_1273228] is asleep.  
b) Evaluation of sleep habits and quality:   The wrist actigraph is worn like a wrist watch and records 
movements during day and night.  The wrist actigraph will be worn for a total of 7 days (+/ -2). A 
sleep diary will be completed while the subject wears the actigraph.  
c) Home noise evaluation:  To me asure the noise inside and outside the home, we will ask the 
participant to place a sound meter. This is a machine that will be placed in the child’s bedroom and 
will record the amount of noise in this space  
 
If a subject  cannot  complete  all activities  at one screening visit,  he/she  may  return within  a week  to comple te the 
remainder  of study  activities.  
 8.3 Home Environmental Assessment: This assessment will done once at any point throughout the subject’s 
participation in the study.  Dust sampling collection from the participant’s bedroom and kitchen.   Home samples will be 
linked to school/class sampling as a surrogate measure for home ex posure and for adjusted analyses.  Home 
 Confidential  Page [ADDRESS_1273229] of home exposure in adjusted analyses with the 
primary focus of this study on the school/classroom specific exposure and clinical outcomes.  
8.4 Randomization .   The DCC  Data  Man agement  System  will randomize  the classroom  to receive active versus sham 
(placebo) air purifiers and the school to receive the IPM intervention.  Randomization  will occur  by [CONTACT_906991].  The randomization  scheme  will be developed  by [CONTACT_906992] (DCC)  and embedded  into the data  
manageme nt system  so that schools and classrooms can be  randomized, linked to enrolled SICAS -[ADDRESS_1273230] Management  (IPM)  
Intervention includes IPM Module of two IPM visits, conducted 4 ±3 weeks apart.  
IPM Interv ention  Visit  1: If the School  has been randomized  to the IPM School,  the study  coordinator  will schedule  an 
IPM visit in the fall after the baseline school sampling.  The IPM intervention  team  will include the Research  Assistant s (RA)  
and IPM Technicians  (IT). The Classroom/School Inspection  Form(s)  will be used  to document  a walk  through  the school in 
order to sketch a layout  and document  visual evidence  of infestation  and holes/cr acks in the structure.  IPM procedures 
will inclu de placement  of traps,   sealing  of holes  and cracks  as specified  in the MOP.  
Our school -based work will focus on the primary exposure school room  of interest, the child’s primary home classroom , 
which is where we focused in our observational findings that provided supporting data for this study.  We 1) inspect 
conditions, record observations, 2) Identify pests, 3) continue follow up and adjust as needed, 4) record observations 
and activities, 5) educate staff.  Focusing on the classroom/cafeteria will also allow us to isolate and control conditions 
focused where the child spends the majority of his/her time.  We will also clean and target IPM on th e heating system of 
the classroom, and evaluate nearby [CONTACT_906993], including cafeteria, and any nearby [CONTACT_906994], boiler rooms, janitor/storage closets if they have evidence of mouse  
infestation.     
IPM Intervention Visit 2 : The second visit of the IPM module will serve as a booster visit and will include an assessment 
of the status of the mouse infestation and repeat setting of traps, , and sealing of holes and cracks.  
Additional IP M Intervention Visits : Subsequent IPM modules will be delivered only if there is persistent or recurrent 
mouse  infestation so that IPM will be tailored to the infestation status of the school.  Mouse infestation will be assessed 
at the follow up school vis its and a school will be considered to have ongoing or recurrent mouse infestation if there is 
evidence of mouse infestation during inspection or if staff reports seeing mice, or evidence of mice, during subsequent 
sampling.   
IPM Accountability : Several  procedures  will be in place  to ensure  adherence  to the protocol, including  timely  and 
appropriate  delivery  of IPM services.  These procedures  include:  
1. IPM  technic ians will undergo  training  and certif ication  prior  to enrollment.  The training  and certif ication will be led by 
[CONTACT_906995] . 
2.  IPM technic ians will be required  to complete  all study  forms  and document  procedures;  forms will be reviewed  by [CONTACT_906996] 10%  will be reviewed  by [CONTACT_906997]  
4.  Annual  site visits  will be conducted  by [CONTACT_906998]  1 IPM visit to 
the schools.  
 Confidential  Page 33 of 69 
 
 
 
SICAS -2  Version 3.0  Date 03.27.15  5.  IPM Company President  or Operations  Manager  will partic ipate in regular  conference  calls  to ensure  timely  
communication  of any protocol  deviations  or issues  that need to be addressed.  
6. For IPM visits,  the visits  and dates  of the visits  will be docu mented.  In addition, the  IPM Technician(s)  will document  
the number  of traps  placed . 
 
8.6 School Environmental Assessment:  Participating schools for the Academic Year  will be scheduled  for a baseline 
school  visit to determine allergen/mold/particulate  exposure  status  in the fall prior to deploying the randomized 
intervention . At the school  visit, a school  environmental assessment  will be conducted, and  settled  dust  and table wipes  
will be collected from  SICAS -2 student’s  home classroom , cafeteria  , and gym,   The air samples  will be collected  from the 
student’s home classroom  to have  a baseline  determination  of airborne  dust. School  environmental assessment includes 
the following procedures:   
Completion  of School  Assessment/Inspection  Form 
 Collection  of settled  dust from cafeteria, primary home classroom and gym.  
 Air pollution, air and mold samples will be collected from the primary home classroom.  
 
The dust  and air samples  from home and school  will be shipped  to Indoor Biotechnologies for allergen  (dust mite, mouse, 
rat, cockroach, cat, dog, alternaria, milk, peanut, egg) /endotoxin analysis . The mold samples will be analy zed at the 
University of [LOCATION_005], Amherst. Particulate Pollutant monitoring samples will be done at HSPH .  
 
A return  school  visit will occur  appr oximately  one week  after  the first school  visit to collect  the air sampling  equipment  and 
samples . Follow -up school environmental assessments will take place once during the fall school semester and one 
during the spring school semester.  
 
8.7 Phone call  surveys : These will be performed in order to collect  health outcomes (e.g., symptoms, health care use; 
time -activity) and home environmental information. They will be conducted   after the start of the school year 
(baseline), and every [ADDRESS_1273231] Follow -up visit :  By [CONTACT_906999] s performed at the screening  visit, we will obtain  
anthropometric measurements (height and weight), Co -oximetry measu rement,  spi[INVESTIGATOR_038], FeNO ,  at the fall and 
spring follow -up visits.  Nasal swab/blow , skin swab , nasorption and buccal swabs will only be performed during the 
spring follow -up visit .  Follow -up clinical assessments will be linked in timing to the environme ntal sampling done 
during the academic year, post randomization. Not only will the timing of the assessments enable us to evaluate the 
effects of the interventions on these outcomes (lung function, FeNO ,) partway through and near the end of the 
interventio n periods.  This timing will also enable us to do secondary analyses on the relation of these outcomes to 
short -term measured school exposures in the different treatment arms.  
These school environmental and clinical measures will enable us to: (1) estimate  the efficacy of the interventions in 
opposite seasons and (2) conduct secondary analyses linking season -specific health outcomes with exposure 
measures rather than treatment group . 
8.9 Focused  Cleaning:  
 Confidential  Page [ADDRESS_1273232]  IPM module,  the research  assistant  will complete  a focused cleaning  aimed  at (1) removing  
allergen  rese rvoirs;  and (2) removing clutter  to aid the IPM technician.  Procedures  will include  removal  of dead mice  
from  traps,  remov al of trash  and clutter,  removal  of mouse droppi[INVESTIGATOR_14839],  wet moppi[INVESTIGATOR_906928]. Our methods are modeled off of success ful  intervention 
work in  homes18  which led to  our NI AID funded Home based study (Mouse Allergen Asthma Intervention Trial 
U01AI083238), and which utilizes successful strategies targeted to the bedroom, inspection targeted in surrounding 
areas, and kitchen.  Our school -based study will focus on the primary e xposure school room of interest, the child’s 
classroom, surrounding support areas, and the cafeteria.   
8.10 Education:  
An educational  module  will be delivered to IPM Schools.  The Educati on SOP which can  be found in the MOP  details  the 
information  to be covered  and the Education  Form will serve  as documentation  of delivery  of the Education Module.   
The module  will review  the approac hes to reduc ing mouse allergen  levels  – source removal,  prevention  of re-entry,  and 
cleaning  of allergen  reservoirs  with school staff . 
8.[ADDRESS_1273233]  a particle  collection  efficie ncy of 99.9%  for particles  as 
small  as 0.3 microns.  All filters  will be replaced  at each  school  visit,  every  3 months,  as recommen ded by [CONTACT_13989]’s  instructio ns. 
 
For the  Classroom Air Filters,  a rese arch assista nt will  assess the units  at the school  visits  to docu ment functio nality  and 
whether the  unit is on and plugged in  at the time  of the school  visit.  Reminders are taped on the units to encourage 
compliance.  If the units are turned off or plugged in , staff will communicate with the school contacts to encourage 
compliance.  
8 . 1 2 Unscheduled Visits  
There  will not be unsc heduled  visits  since  the study will not be managing  the study participant’s  asthma.  Instead,  
documentation  of the study  participant’s  primary  care provider  will occur  at the screening  clinic visit and participan ts who  
do not identify  a primary  care  provider  will be referred  to one.  A participant  who contacts  study  staff  with acute  health  
concerns  will be referr ed to his/her  primary  care  provider  or the Emerg ency Department,  depending  on nursing  or 
physician  judgment.  
8.13 Laboratory Reference Ranges:  We will use age and sex specific published standard reference ranges for all clinical 
labs to define out of range safety lab values in the clinical database. Laboratory results will also be reviewed by [CONTACT_978] [INVESTIGATOR_906929] -up promptly with the family regarding any 
abnormal results that require medical intervention. The original lab results reports for each participant will be signed 
and data to verify they have been reviewed and action taken where  appropriate.  
Schedule of Events :   
 Confidential  Page 35 of 69 
 
 
 
SICAS -2  Version 3.0  Date 03.27.15  Table 2 Surveys
 
      
 
Table 3 Clinical Procedures  Screening  
(Jun -Sep)  Randomizat
ion School 
Follow -Up 1  
(Dec -Feb)  School 
Follow -Up 2  
(Mar -Jun) 
Participant Baseline Visit Data  and Sample  Collection  
 CBC/Allergen specific  IgE 
 Serum, plasma, urine and saliva for storage  
 Nasal swab and blow  
 Skin swab  
 nasoprtion  
 Buccal Swab  (optional)  
 Height, Weight, Heart rate, Pulse Oximetry  
 Skin Allergy Test  X  
  

 Confidential  Page 36 of 69 
 
 
 
SICAS -2  Version 3.0  Date 03.27.15   Pre/Post Albuterol Spi[INVESTIGATOR_038]  
 Nasal Brush (optional)  
Participant Follow -up Visit Data Collection  
 Spi[INVESTIGATOR_038]  
 FeNO  
 CO-oximetry  X  
X X 
Participant Follow -up Visit Sample  Collection  at School  
 Nasal Swab and Blow  
 Buccal Swab  
 Skin swab  
 nasorption    
 X 
Participant Follow -up Clinic Visit Sample Collection  
 Nasal Brush (optional)  done in clinic  only    <----------  -----------  > 
  
 
 
  
 Confidential  Page 37 of 69 
 
 
 
SICAS -2  Version 3.0  Date 03.27.15        Table 4 : Environmental Measures and Forms (School, Classroom, and Home)  
Measure  Baseline   
(Oct -Nov)  Randomiza
tion Follow -Up 1  
(Dec -Feb)  Follow -Up 2  
(Mar -Jun) 
School Contact [CONTACT_907000]  X    
School /Classroom  Evaluation  X  X X 
School Environmental Samples  X  X X 
Home Environmental Samples - Vacuum Dust**  <-----------   --------------  -----------  > 
**One home dust sample is taken at any time during the year  as a surrogate measure for home exposure  
 
9. Mechanistic Assays  
Rationale:  
 Mechanistic Background Data Methylation and gene expression  to environmental responses Epi[INVESTIGATOR_1663] (ECs)93, 94 
provide the front -line physical, immune, and chemical barrier to the allergen and irritant exposures that we will reduce82, 
89. Pattern recognition receptors (PRRs: TLRs, NOD -like receptors, C -type lectins; protease -activated receptors) on ECs 
recognize proteolytic allergens and allergen -associated microbia l contaminants, with EC release of innate cytokines (e.g., 
TSLP,CM -CSF, IL -25, IL -33) that can activate dendritic cells and increase Th2 cytokine expression, or activate basophils, 
mast cells and eosinophils involved in allergic/asthmatic responses. Altere d EC barrier function with tight -junction 
disruption is linked to poor ciliary clearance or increased mucous production in asthma. EC innate96,97, barrier, and repair 
function may be dysregulated by [CONTACT_907001]98. 
 Gene expression is regulated in part by [CONTACT_907002][INVESTIGATOR_232882] (e.g., by [CONTACT_387282], as well as 
by a coordinated suite of less accessible epi[INVESTIGATOR_906930]). Both can be 
influenced by [CONTACT_907003],99-[ADDRESS_1273234] shown that within -person methylation  of 
PRRs (TLR4) is decreased with particle pollution exposur e104. We found higher airway inflammation (FENO) was 
associated with  methylation of the innate pro -inflammatory cytokine IL -6 (29.0%; p=0.004) and iNOS in asthmatic 
children79. While epi[INVESTIGATOR_906931], we have demonstrated plast icity in 
methylation of other genes, with changes that begin with short -term exposures and become greater with cumulative 
exposure over months105-113. 
 
  
 
I Mechanistic Assays : This would be the first trial assessing how school -based interventions (integrated pest 
management and/or reduction in classroom particles levels)  influence changes in methylation and downstream gene 
expression pathways or networks of genes that, in turn, have relevance to reduction of asthma morbidity and 
improvement in the natural course of the disease. Application of bioinformatic techniques will  enable us to discover pre -
specified as well as novel pathways of genes that respond to our intervention with changes in methylation and/or 
 Confidential  Page [ADDRESS_1273235] biomarkers83, 114, utilizing samples that  can be obtained from children non -invasively, rather than by [CONTACT_907004].  
 
Health Outcomes from Students in Entire C lassrooms (Exploratory):  
Secondarily, depending on scheduling with the school, we will redistribute  surveys to entire classrooms of the  same 
classrooms/schools that we are collecting environmental dust/air sampling data during the academic year. This wil l 
allow us to have a one follow up measure of health outcomes form the entire classrooms, linked to the environmental 
sampling.  This will provide us with symptoms (including nasal) from the students without asthma that are enrolled in 
the study.   
This all ows to efficiently obtain health outcome data of our intervention in entire classrooms of these students.  In 
SICAS -1, most of classrooms of students in our study had at most 2 -3 students in a classroom of 20 students. Although 
these outcomes are not the p rimary specific aims of SICAS -2, this will allow us to assess preliminary respi[INVESTIGATOR_906932], linked to our intervention and preliminarily determine the intervention on 10 -20 times 
the number of enrolled SICAS -2 students wit h asthma or 3000 -6000 students, and greatly leverage the wealth  of 
information on determining the effectiveness of our intervention in a community of students.  
10. Biospecimen  Storage  
Serum, plasma, saliva, urine and buccal brushes, nasal swab and blow samples will be stored using unique identifiers. 
These samples will be s tored at BIOCORE part of Children’s Hospi[INVESTIGATOR_906933].  Samples will be saved for 
future analyses such as immune markers such as pro -inflamm atory cytokines such as IL -6, IL-33, leptin, basophils, TNF α, 
IFN-γ and other cytokines, stress markers such as salivary cortisol and  α -amylase, serum gender specific hormones (i.e. 
E2,DHEAS,testosterone, SHBG, Progesterone) urinary metabolomics, proteom ics, urinary chemicals (  BP-3, BPA, 
Butylparaben, Ethylparaben, Methylparaben, Propylparaben, Triclosan, 2,4 -dichlorophenol and 2,5 -dichlorophenol, 
ispoprotenes, pesticides, benzenes, leukotrienes , and creatinine), and buccal brushes saved for epi[INVESTIGATOR_7009]/ RNA gene 
expression,  and nasal swab/blow samples saved for viral, microbial, and bacterial organism analysis,  which may help us 
further our understanding of mechanisms behind the interventions, pending future funding  
 
11. Criteria for Participant and Study Com pletion and Premature Study Termination  
11.1. Participant Completion  
Subject who has completed summer baseline  clinical  and clinical follow up through the entire subsequent academic 
school year has completed the study  as long as they remain in the school classro om where the intervention and 
 Confidential  Page [ADDRESS_1273236] randomization of intervention linked to classroom exposure sampling.  
11.2. Participant Stoppi[INVESTIGATOR_457375]:  
1. Voluntary  withdrawal  by [CONTACT_907005].  Every  effort  
will be made  to collect  clinical and AE data  via telephone.  
2. The participant is “lost to follow -up” (i.e., no further follow -up is possible because attempts to reestablish 
contact [CONTACT_73880]).   After up to [ADDRESS_1273237]  completed  one follow up clinical visit after the school /classroom has been randomized to 
the environmental intervention  will not be replaced . Participants who withdraw or are withdrawn will not  be replaced . 
11.4. Follow -up after Early Study Withdrawal  
Voluntary  withdrawal  by [CONTACT_907005].  Every  effort  will be 
made  to collect  clinical and AE data  via telephone.  
 
11.[ADDRESS_1273238] a priori study stoppi[INVESTIGATOR_906934] .  If we learn of new information that would make the intervention unsafe (unlikely in an 
environmental intervention study , but i.e. a severe adverse event directly related to the intervention ), that could also 
warrant stoppi[INVESTIGATOR_906935].    
12. Overview  
 
This section defines the types of safety data that will be collected under this protocol and outlines the procedures for 
appropriately collecting, gradin g, recording, and reporting those  data. Adverse events that are classified as serious 
according to the definition of health authorities must be r eported promptly (per Section 12 .5, Reporting of Serious 
Adverse Events  and Adverse Events ) to the sponsor DAIT/NIAID.  Appropriate notifications will also be made to site PI , 
Institutional Review Boards (IRBs), and health authorities.  
Information in this section complies with ICH Guideline E2A: Clinical Safety Data Management: Definitions and Standards 
for Expedited Reporting, ICH Guideline E -6: Guideline for Good Clinical Practice, 21CFR Parts 312 and 320, and applies 
 Confidential  Page 40 of 69 
 
 
 
SICAS -2  Version 3.0  Date 03.27.15  the standards set forth in the National Cancer Institute (NCI), Common Terminology Criteria for Adverse Events (CTCAE), 
Version [enter 4.[ADDRESS_1273239] version applicable to trial ] : http://ctep.cancer.gov/reporting/ctc.html . 
12.1 Definitions  
12.1.1 Serious Adverse Event (SAE)  
An adverse event  or suspected adverse reaction is considered “serious” if, in the view of either the investigator 
or Sponsor( DAIT/NIAID) , it results in any of the following outcomes (21 CFR 312.32(a)):  
1. Death.  
2. A life -threatening event: An AE or SAR is considered “life -thre atening” if, in the view of either the 
investigator or Sponsor( DAIT/NIAID) , its occurrence places the subject at immediate risk of death. It does 
not include an AE or SAR that, had it occurred in a more severe form, might have caused death.  
3. Inpatient hos pi[INVESTIGATOR_1081].  
4. Persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions.  
5. Congenital anomaly or b irth defect.  
6. Important medical events that may not result in d eath, be life threatening, or require hospi[INVESTIGATOR_20967], based upon appropriate medical judgment, they may jeopardize the subject and 
may require medical or surgica l intervention to prevent one of the outcomes listed above.  
Asthma hospi[INVESTIGATOR_906936] . 
 
12.1.2 Adverse Event (AE)  
Any untoward or unfavorable medical occurrence associated with the subject’s participation  in the research, whether or 
not considered related to the subject’s participation in the research (modified from the definition of adverse events in 
the 1996 International Conference on Harmonization E -6 Guideline s for Good Clinical Practice) (f rom OHRP " Guidance 
on Reviewing and Reporting Unanticipated Problems Involving Risks to Subjects or Other s and Adverse Events 
(1/15/07)"  http://www.hhs.gov/ohrp/policy/advevntguid.html#Q2  )  
For this study, recorded and reported as an adverse events are limited to 1.) any occurrence or worsening of an 
undesirable or unintended sign (including an abnormal laboratory finding), symptom, or disease in a study subject that is 
specifically associated (possible, or definite – defined in sectio n 10.2.2.) with a study procedure; 2) Asthma 
exacerbations that require hospi[INVESTIGATOR_906937] a 
SAE and 3) SAEs which are not asthma exacerbations ..  
Study therapy regimen :  Environmental In tervention, generally not applicable . No treatment given as part of this study.  
 Study mandated procedures :  blood draw, nasal sample,  skin swab,  nasorption and lung function test.  
For the procedures below, clinical situations are listed that are consider ed to be outside the 
normal range of outcomes  and will be recorded as Adverse Events.  These situations do not 
limit an investigato r from recording and reporting any other events, associated or not with 
these procedures as AEs.    
 Confidential  Page 41 of 69 
 
 
 
SICAS -2  Version 3.0  Date 03.27.15  Allergen Skin Testing  
 Prolonged (>24 hours) itching at test site  
 Swelling (> 10 cm ) at site of test lasting more than 24 hours  
 Nasal allergic symptoms within 30 minutes from the procedure  
 Fainting /Vasovagal event within 30 minutes from the procedur e 
 
Blood Draw  
 Fainting/Vasovagal events  
 Bruising at puncture site larger than 2 cm diameter  
 Bleeding from puncture site lasting more than 30 minutes  
 Swelling at puncture site larger than 2 cm  
 
Pulmonary Function Testing  
 Wheezing or bronchoconstriction requiring treatme nt with bronchodilators within 30 minutes from 
the procedure  
 Coughing requiring treatment with bronchodilators within 30 minutes from the procedure  
 
Nasal Epi[INVESTIGATOR_765896]  
• Epi[INVESTIGATOR_4384] 24 hours after the procedure  
 
 
[IP_ADDRESS] Suspected Adverse Reaction (SAR)  
N/A 
12.2.2 Unexpected Adverse Event   
Not Applicable.  
12.2.1 Grading Criteria  
The study site will grade the severity of adverse events experienced by [CONTACT_73881]’s Common Terminology  Criteria for Adverse Events (CTCAE)  
version 4.0.  This document (referred t o herein as the NCI -CTCAE manual) provides a common language to 
describe levels of severity, to analyze and interpret data, and to articulate the clinical significance of all adverse 
events. The NCI -CTCAE has been reviewed by [CONTACT_100615] [INVESTIGATOR_906938].   
Adverse events will be graded on a scale from 1 to 5 according to the follo wing standards in the NCI -CTCAE 
manual:  
Grade 1 = mild adverse event.  
 Confidential  Page 42 of 69 
 
 
 
SICAS -2  Version 3.0  Date 03.27.15  Grade 2 = moderate adv erse event.  
Grade 3 = severe and undesirable adverse event.  
Grade 4 = life -threatening or disabling adverse event.  
Grade 5 = death.  
All AE’s related to study procedures  will be recorded on the appropriate AE case report form   for this study.  
For grading an abnormal value or result of a clinical or laboratory evaluation (including, but not limited to, a 
radiograph, an ultrasound, an electrocardiogram  etc.), a treatment -emergent adverse event is define d as an 
increase in grade from b aseline or from  the last post -baseline value that doesn’t meet grading criteria. Chan ges 
in grade from screening to baseline  will also be recorded as adverse events , but are not treatment -emergent. If 
a specific event or result from a given clinical or laboratory evaluat ion is not included in the NCI -CTCAE manual, 
then an abnormal result would be considered an adverse event if changes in therapy or monitoring are 
implemented  as a result of the event/result . 
12.2.2 Attribution Definitions  
The relationship, or attribution, of an adverse event to the  study procedure(s) will initially be determined by [CONTACT_907006]/SAE paper CRF .  Final determination of 
attribution for safety reporting will be determined by [CONTACT_73884]/NIAID  Medical Monitor (MM) .  The relationship of an 
adverse event to study therapy regimen or procedures will be determined using the descriptors and definitions 
provided in Table 12 .2.2.  
For additional information and a printable version of the NCI -CTCAE manual, consult the NCI -CTCAE web site: 
http://ctep.cancer.gov/reporting/ctc.html  
 
       Table 12. 2.2 Attribution of Adverse Events  
Code  Descriptor  Relationship (to study procedure ) 
UNRELATED CATEGORY  
[ADDRESS_1273240] a causal 
relationship  
 RELATED CATEGORIES  
2 Possible  The adverse event has a reasonable possibility  to be 
related; there is evidence to suggest a causal 
relationship.  
[ADDRESS_1273241]  completes study participation or 
until 30 days after he/she prematurely withdraws (without withdrawing consent) or is withdrawn from the 
study.  
12.4.2 Collecting Adverse Events  
Adverse events (including SAEs) may be discovered through any of these methods : 
• Observing the subject.  
• Interviewing  the subject [e.g., using a checklist, structured questioning, diary, etc.]   . 
• Receiving an unsolicited complaint from the subject.  
• In addition, an abnormal value or result from a clinical or laboratory evaluation can also indicate an adverse  
event, as defined in Section [ADDRESS_1273242] adverse events and serious adverse events as described 
previously (Section 12 .2, Definitions) on the appropriate  case report form AE/SAE paper CRF  regardless of the 
relationship to study therapy regimen or study procedure.  
Once recorded, an AE/SAE will be followed until it resolves with or without sequelae, or until the end of study 
participation, or until [ADDRESS_1273243] prematurely withdraws (without withdrawing consent)/or is 
withdrawn from the study, whichever occurs first.  
12.5 Reporting of Serious Adverse Events  and Adverse Events  
12.5.1 Reporting of Seri ous Adverse Events to Sponsor (DAIT/NIAID ) 
This section describes the responsibilities of the site investigator to report serious adverse events to the sponsor 
(DAIT/NIAID) via (Case Report Form , facsimile,   hotline -mail ).   Timely reporting of adverse events is required by 
21 CFR and ICH E6 guidelines.  
Site investigators will report  to the NIAID Medical Monitor   all serious adverse events  (see Section 12 .1.3, 
Serious Adverse Event) , regardless of relationship or expectedne ss within [ADDRESS_1273244] information for NIAID Medical Monitor : 
PETER GERGEN , MD, MPH  
Division of Allergy, Immunology, and Transplantation – NIAID/NIH  
[ADDRESS_1273245]  
Bethesda, MD [ZIP_CODE] -9828 , [LOCATION_003]  
Phone:  [PHONE_17986]  
Fax:  [PHONE_1895]  
E-mail:  [EMAIL_2091] ] 
For serious adverse events, all requested information on the AE/SAE  Case Report Form will be provided.  
However, unavailable details of the event will not delay submission of the known information.  As additional 
details become available, the AE/SAE case report form will be updated and submitted.  
 Confidential  Page 44 of 69 
 
 
 
SICAS -2  Version 3.0  Date 03.27.15  [IP_ADDRESS] Reporting of Unexpected Non -Serious Adverse Events  
Any non-serious adverse event that is of Grade 2  severity or higher and study related  will be recorded 
and reported to the NIAID Medical Monitor under the serious adverse event reporting procedure above  
(i.e. within 24 hours).     
12.5.2 Reporting to Health Authority  
Not Applicable  
12.5.3 Reporting of Adverse Events to IRBs  
All investigators shall  report adverse events, including expedited reports, in a timely fashion to their 
respective IRBs/IECs in accordance with applicable r egulations and guidelines.  
12.7 Reporting of  Unanticipated  Safety Informati on 
An investigator shall promptly notify the site  IRB as well as the  DAIT/Medical Monitor and Data Management 
and Analysis Core  when an “unanticipated problem involving risks to subjects or others” is identified, which is 
not otherwise reportable as an ad verse event.  
12.8 Review of Safety Information  
12.8.1 Medical Monitor Review  
The NIAID Medic al Monitor shall  receive quarterly  reports from the  PI/Protocol Chair compi[INVESTIGATOR_906939] , SAEsrecorded by [CONTACT_907007].  
In addition, the  NIAID  Medical Monitor shall  review and make decisions on the disposition of the SAE received 
by [CONTACT_32816] [INVESTIGATOR_906940]  (See Sections 12 .5.1, Reporting of  Serious Adverse Events to 
Sponsor  (DAIT/NIAID) ).   
12.8.[ADDRESS_1273246] (DDSMB) Review  
[IP_ADDRESS]  Planned Data and Safety Monitoring R eviews  
The Data and Safety Monitoring Board (DSMB)  shall  review safety data at least yearly during planned 
DSMB  Data  Review Meetings. Data for the planned safety reviews will include, at a mini mum, a listing of 
all reported AEs and SAEs.   
[IP_ADDRESS] Ad hoc  DSMB  Reviews  
In addition to the pre -scheduled d ata reviews and planned safety monitoring, the DSMB may be called 
upon for ad hoc  reviews. The DSM B will review any event that potentially impact s safety at the request 
of the Protocol Chair or the NIAID  Medical Monitor . In addition, the following events will trigger an ad 
hoc comprehensive DSM B Safety Review:  
o Any death t hat occurs in the study , which is possibly or definitely related to study treatment 
regimen.  
o The occurrence of a Grade [ADDRESS_1273247] and/or 
continuation.  
[IP_ADDRESS].[ADDRESS_1273248] stop due to safety reasons.  
13. Statistical Considerations and Analytical Plan  
13.1  Overview  
Note:  SICAS-1 (School Inner -City Asthma Study)  refers to observational R01 (AI 0739654, Phipatanakul), and SICAS -2 
(School Inner -City Asthma  Intervention Study)  is the proposed clinical trial.  
The primary  objective  of SICAS -[ADDRESS_1273249] Management (IPM)  and Class room Air 
Filters  in reducing  asthma  morbid ity in school  children  with  asthma. Reducing  school/classroom  mouse, mold  allergen  and 
particulate pollutant exposu re will be assoc iated  with  improvement  in asthma  outcomes.   
Our mechanistic objective is to test the hypothesis that effects of school/classroom -based environmental interventions 
on symptoms/other measures of asthma control occur through changes in gene methylation or expression in pathways 
(and seconda rily, in genes) relevant to airway function (Research Strategy  Section  1.4) and asthma.  
13.2  Outcomes (Described in 3.2 -3.4) 
Primary Outcome(s)  
 
13.3  Measures to Minimize Bias   
Rand omization:  Schools will be randomized to IPM vs no IPM, and within schools,  participant classrooms will be randomized to HEPA filter vs 
Sham Air Cleaner  within  three  weeks  of the baseline school  visit in a 1:1 ratio  using a statistical software  package  to 
generate  random numbers.  The randomization  sche me will be developed  by [CONTACT_543940]  
(DMAC).  [CONTACT_907036], MD, MPH, DrPH  and her team   will lead the DMAC  and assistance from [CONTACT_907037]’s team from the Clinical Research Information Technology Team will  provide support for  database programm ing 
for the trial and program the forms for data capture using REDCap. Carter Perry, MA will provide the statistical 
programming.      
Maintenance of Trial Treatment Randomization Codes  
The randomization  scheme will be embedded  in the data  tracking  system  and access  to the  scheme  will be restr icted  to 
the DMAC  database  progr ammer.  In addition,  once  a school or participant classroom  has been  randomized,  the group  
assignment  will be locked.  The randomization  codes  may  only  be broken  at the request  of the Data Safety Monitoring 
Board (DSMB)  and the minimum number  of DMAC  staff  necessary  will be unmasked  in order  to provide  requested 
analyses  to the DSMB . 
 Confidential  Page 46 of 69 
 
 
 
SICAS -2  Version 3.0  Date 03.27.15   
Masking  : The Air Filter Classroom Intervention involves double -blinding, with placebo controlled randomization. The 
Sham Air Cleaner is designed to emit the same quiet background sound as the HEPA filter Air Cleaner. Staff from the HSPH 
Environmental Assessment and  Intervention Core who do not have contact [CONTACT_907008] 3 months at the school after school hours, ensuring participants, PI, and study staff are 
blinded to classroom intervention assignment.   
For IPM, the benefit of SICAS -2, compared to home -based interventions in which masking is impossible, is that it will be possible 
to single blind  and mask the School IPM procedures. Students will not know whether or not IPM is being applied at the 
school ---IPM procedures are done after hours when the students are not in school.  Although  it may  be possible  to 
attempt  to mask  some study  staff  from knowledge of IPM treatment by [CONTACT_907009] (so that 1-2 RAs who ascertained clinical outcomes would not be involved in tasks related to IPM) this  would  
substantially increase  the budget. Thus double -blinding for IPM is not feasible or practical even in a school based study.  
There  are also several  aspects  of the study  that will guard  against  bias that could  result  from  having  unmasked  study  staff.  
First,  all labo ratory  assays  will be conducted  by [CONTACT_907010].  Second, 
some  of the clinical  data  that are collected,  including  exhaled  nitric  oxide and pre- and post - bronc hodilator  spi[INVESTIGATOR_906941]. Third,  secondary 
analyses  will be conducted  to determine  if any impr ovements  in clinical outcomes  are associated  specifically  with 
decreases  in school  allergen, mold or other pollutant  levels,  not just with group  assignment.  
While randomization should result in minimal differences between treatment groups in home allergen levels, we will 
measure home allergens levels  and these measures will enable  us to control for any residual confounding by [CONTACT_907011].  Home samples will be linked to participants  as a surrogate measure for home exposure and 
for adjusted analyses.  Home environmental assessments will also be done to differentiate the effect of home exposure 
in adjusted analyses with the primary focus of this study on the school/classroom specific exposure and clinical 
outcomes.   
All laborato ry studies  (allergen  ELISAs, allerge n-specific  IgE levels,  endotoxin  levels,  PM 2.5, Black Carbon  level s, trace 
elements,  NO 2 levels, and mold)  will be performed  in central ized laborator ies in batch es to minimize  variability  of the  
assay.  
13.4  Analysis Plan  
13.4.1  Analysis Populations . 
Analyses  will be performed  using  an intent -to-treat (ITT)  dataset  which  will include  all participan ts who  are randomized. 
Analyses  will be performed  using  a per-protocol  (PP) dataset  and an intent-to-treat  (ITT) dataset.  The primary  analysis  
will be an ITT analysis.  After ensuring that any dropout is missing completely at random (see Missing Data Considerations below). 
The ITT dataset  will include  all participan ts who  are randomized,  and the per-protocol  dataset  will inclu de only 
participan ts who  have  completed  at least  one intervention  visit (one  IPM/ Air Purifier visit) and one follow up clinical 
outcome visit.  
13.4.2  Primary Analysis of Primary Endpoint (s)   
 Confidential  Page 47 of 69 
 
 
 
SICAS -2  Version 3.0  Date 03.27.15   
Multi -Level Modelling:  
We will employ multi -level models140 to quantify the effects of interventions (both class -specific filters and school -wide 
IPM) on the clinical outcomes, while accounting for the multiple levels (school, classroom, student, time point) of data.  
Specifically, we will employ non -linear mixed effects models, which intrinsically handle unbalanced data (unequal 
number of classro oms within schools and unequal number of children with asthma within classrooms) while accounting 
for child, class, and school -level variability (clustering) in the outcome by [CONTACT_907012].  
SICAS -1 generally had no more than on e to two SICAS asthma students per classroom, so that clustering by [CONTACT_907013].  Count data (such as our primary symptom 
outcome) will be analyzed by [CONTACT_907014].  Our 
primary analysis will contrast outcome levels in the intervention and control arms. For symptom -days, we will use the 
negative binomial regression:  
(Model 1): log E[Y ijcs] = b 0 + b 1sch s + b 2clsc + b 3sch s * post j + b 4clsc * post j + aTzij+ u s + w ics 
 
where Y ijcs  is the number of symptom days for subject i in class c and school s on visit j, sch sj is the indicator of IPM 
treatment for school s, cls c is the class -specific filter treatment for class c at visit j, post j is an indicator variable for post -
(versus pre -) randomization for a given visit, and z ij is a vector of potential confounders, including seasonal influences 
captured by [CONTACT_305574] (1 -5), and, in the unlikely event that home exposures are not balanc ed across treatment arms, 
home exposures. Visit number is the visit (0,1,2,3,4) on which a given measurement was recorded (reflecting time of year 
at which measurement was taken), as opposed to post which is 0/1 representing pre/post.   In this model the mai n 
intervention effects (sch s, cls c) represent differences at baseline and allow us to check for imbalance in the 
randomization.  Post is 0/1 for  pre/post regardless of the tim ing of the post visit. We include visit number as a covariate 
into the analysis to  account for the timing of each observation.  The terms u s and  w ics  represent school -specific and 
subject -specific random effects, respectively, to account for longitudinal correlation among measurements taken on the 
same subjects (w ics) and among measure ments taken on different subjects within the same school (u s). As is tradition al 
in non -linear mixed effects models, we will assume each set of random effects are normally distributed with unknown 
variance estimated from the data. We will use standard diag nostic methods to check this normality assumption, with 
some of these having been developed by [CONTACT_27156].   In the likely event that there is balance in symptoms at baseline 
and the effects are absent, we can re -fit the model removing these main effects. T he sch*post and cls*post terms are 
the terms of scientific interest and represent how post vs pre randomization changes in symptoms rates differ between 
intervention and control arms.   Because we include visit number as a main effect we do not need to inc lude the main 
effect of post -randomization. We note that this model is standard for longitudinal pre -post randomization designs141. 
Again, we will add class -specific random effects if subjects are clustered significantly within classrooms within a school. 
For continuous outcomes such as lung function, we will fit analogous linear mixed effect models , which takes the form  
 
         (Model 2) : Yijcs = b 0 + b 1sch s + b 2clsc + b 3sch s * post j + b 4clsc * post j + aTzij+ u s + w ics+ e ijcs, 
where the covariates are defined as above for the negative binomial model and eijcs are normally distributed errors .  
Extensions for secondary analyses (a) -(d) will be handled an alogously to those for model (1) ( Please s ee secondary 
analyses section ). Standard diagnostics will be applied to detect non -normality of the errors, but experie nce suggests 
that this distributional assumption will be appropriate for lung function outcomes.  Our primary analyses will entail fitting 
the models (1) and (2), with Z i  terms including visit number (as a categorical variable) and home exposures that 
 Confidential  Page 48 of 69 
 
 
 
SICAS -2  Version 3.0  Date 03.27.15  correspond with the same exposure in school (ie. classroom/school mouse exposure adjusting for home mouse 
exposure).  As written, these models will include the cls and sch intervention terms.  Secondary analyses will include (a) 
the effect of intervention vari es by [CONTACT_907015](visit/survey 1 -5) (b) exposure concentrations as predictors,(c) whether 
the effect of intervention or exposure concentration is modified by [CONTACT_907016], 
and (d) assess whether there is a synergisti c effect of the classroom and school -wide interventions.   The terms  Z ij will 
not include any post -baseline patient measurements that can be influenced by [CONTACT_15500].  The terms to be 
include in this vector will include visit number as a categori cal variable, and home exposures.  We will test b 3 and b 4 in 
separate hypothesis tests.  
 
Missing Data Considerations:  
Missing Data: Missed  study visits  and drop -outs  will occur,  and if these  events  occur  completely  at random  or at  random,  
then  the use of multi -level models in the primary  anal yses will produce consist ent estimates  of the treatment  effects  and 
tests of these  effects.    It will be extremely rare, if it happens at all, that we will have symptom data for a subject just at 
baseline with no post -baseline measures. The only time this would happen is if a subject moves to a non -participating 
school for that academic school year.  If this does occur we will first investigate whether dropout is associated with any 
covariates.  If it is, then to o btain valid inferences for the intervention, we will have to control for those covariates 
explaining the missingness (see Fitzmaurice, Laird, Ware, Chapter 17 -18).  If it is completely at random (MCAR dropout), 
then it is acceptable to remove  that subject from the analysis and only patients with some post -baseline symptom data 
will contribute to the primary analysis . As sensitivity analyses, we will conduct analyses using inverse probability 
weights, which effectively up -weights subjects that are more likel y to dropout142.  We may also have missing covariates, 
as opposed to dropout.  The main tool for adjusting for missing covariate data will be multiple imputation methods, 
which can now be easily implemented in SAS (PROC MI and PROC MIAN ALYZE).  
Multiple Comparisons:  For symptoms, we have defined a single primary endpoint for analysis and no multiple 
comparisons adjustment will be made.  For the mechanistic component, we will run the analysis separately 
for each endpoint and each DNA met hylation mediator and will adju st for multiple comparisons  using False 
Discovery Rates148  
13.4.3  Supportive Analyses of the Primary Outcome   
The primary  clinical  outcome  measure,  max imum  number  of days  of symptoms  in the preceding  two weeks,  will be 
assessed  in relation to classroom/school  allergen/mold/particulate levels.   The primary  analysis  will be conducted  using  the 
values  of the primary outcome  at the 2,  4, 6, and 8  month  follow -up surveys. The 10 month survey can be used in tertiary 
analyses to assess for carry -over effects.  
13.4.4  Analyses of Secondary and Other Endpoint (s)/Outcome(s)  
Secondary analyses will include (a) the effect of intervention varies by [CONTACT_907015] (visit 1 -5) (b) exposure 
concentrations as predictors, (c) whether the effect of intervention or exposure concentration is modified by 
[CONTACT_907017], (d) assess whether there is a synergistic effect of the classroom and 
school -wide interventions.  In (b), exposure concentrations will be matched to health outcomes according to the season 
in which a particula r visit falls. Our preliminary data from SICAS -[ADDRESS_1273250] intervention effects, as SICAS -1 
analyses showed significant effects  using this same design/plan.  Also, our preliminary intervention study demonstrated 
exposure reductions of ≥ 75%. This is greater than any seasonal variability demonstrated in classroom exposures in 
SICAS -19, 22, and will allow us to detect the effects of our intervention, regardless. For (c), we will add sensitization, 
sensitization*visit number, sensitization*cls c, and sensitization*sch s   terms to the model.  For (d), to models (1) and (2) 
we will add cls c * sch s  and  cls c * sch s * post j   interaction terms.  
Other  factors that  may  modify the effect  of the intervention  on outcomes  include  level  of mouse  allergen exposure,  
number  of other  allergic  sensitiviti es, ( i . e .  the combination  of cat exposure+sensitiza tion, and /or the combination  of 
cockroach  exposure+se nsitization). Additional  clinical char acteristics that  might  affect  responsiveness  to the intervention  
include  severity  of asthma,  lung  function, and  FeNO  concentrations.  Analyses  will again include interaction  terms  in 
models  to determine  of any of these  factors  predict responsiveness  to the intervention.   
In seconda ry analyses,  we will adjust for factors  that may  affect  responses  to treatment  such  as the degree  of exposure  at 
baseline,  the degree  of sensi tivity to mouse,  number  of other  allergies,  and asthma  severity.  Because  hospi[INVESTIGATOR_213980],  ED 
visits, unschedul ed visits,  and corticoster oid bursts  are relatively  infrequent  events,  we will assess  the distribution  of 
these  variables  and may  decide  to dichotomize  the outc ome as any vs. none  and use  logistic  models.  
Other secondary  clinical outcome  variables  that will be examined  will include those listed above in Table [ADDRESS_1273251]  on the relationship 
between  group  assign ment and the outcome.  Some  specific  confounde rs that will be carefully examined  include,  
cockroach sensitization  and exposure (SICAS -1 had minimal to no cockroach exposure in schools and homes9), 
medication  use, upper and lower respi[INVESTIGATOR_18073], changes  in exposure  to other  pollutants  and other allergens (note 
that cat and dogs as pets in schools are not allowed but exposure levels from home and school will be available),  
environmental tobacco smoke exposure (smoking in schools is banned), home exposures,  and endotoxin  levels, age, 
gender, race, household income , perceived stress29, body mass index144, and season. Effect  modifiers,  inclu ding the 
degree  of allergen /pollutant  reduction,  will also be examined  by [CONTACT_907018].  
 
Mechanistic Outcome Analysis:  
Mechanistic Analytical Plan:  
Pathway analysis : Analysis of the data from the mechanistic portion of the study will focus on pathway -specific effects 
of the intervention on genome -wide methylation  and expression,  and their downstream effects on asthma symptoms . 
Because we will have genome -wide methylation  and mRNA expression  data collected before and after the intervention, 
analyses will apply to post -pre differences in site -specific methylation and expression, and assess whether these 
differences relate to intervention group  and asthma symptom . Within this design, in order to uncover pathways or 
 Confidential  Page 50 of 69 
 
 
 
SICAS -2  Version 3.0  Date 03.27.15  methylation /expression  signatures associated with the intervention  and asthma symptom reduction , we will  perform (1) 
a semi -supervised pathway analysis and (2) an unsupervised methylation/expression  signature [CONTACT_14618]. These analyses 
will use all available genes on the chip but can also be used to examine association with candidate pathways. DNA 
methylation and mRNA expression will be analyzed separately and their results will be cross reference d to interpret the 
function of genes identified.  
Pathway perturbed by [CONTACT_907019], we will first cross reference association results with intervention and 
asthma symptom to identify pathways and gene networks that are perturbed by [CONTACT_907020]. In addition to es timating the association of methylation and expression with 
each intervention and with asthma symptoms, we will also estimate how much the intervention effect on asthma 
symptoms is through methylation/expression changes using causal  mediation analysis . Based on the theory of 
counterfactuals (e.g. what a subject’s methylation/expression and symptoms would have been if that person had been 
instead randomized to the opposite treatment arm), we will apply the VanderWeele and Vansteelandt80 approach, 
which is very general in that it  allows for the possibility of intervention -mediator (methylation/expression in this case) 
interactions on symptom outcomes, to estimate the direct and indirect (through a methylation/expression mechanism ) 
effect of intervention  on asthma symptoms (or othe r clinical endpoint).  These models will include both interventions 
(classroom air filter and school -wide IPM).  In the absence of intervention and methylation/expression interaction, this 
approach reduces to the well -known approach of Baron and Kenney79.  This class of models, which can be easily 
extended to count outcomes via Poisson or negative binomial regression and also to include random effects to account 
for the longitudinal design of the study, is one with which our investigative team has extensive  prior experience104, [ADDRESS_1273252] modification due to sensitization and related phenotypes  
We will repeat the above association analyses by [CONTACT_907021]. 
In model assessing the  association of intervention with methylation and gene expression, the interaction term in the 
model will be each intervention indicator by [CONTACT_907022]. For association of asthma symptom 
and methylation and expression, the interacti on term in the model will be methylation/expression and sensitization and 
related phenotypes. We will also characterize subjects based on their methylation/expression patterns at baseline 
before intervention. We expect that part of these patterns might ref lect epi[INVESTIGATOR_906942], T H2 or 
other functions measurable in nasal samples . We will examine whether molecular characteristics before intervention 
modifies the size of effect and influences which gene pathways are changed by [CONTACT_907023].     
Correction of potential confounding due to cell counts and batch effects  
 Confidential  Page 51 of 69 
 
 
 
SICAS -2  Version 3.0  Date 03.27.15  Although we will completely randomized the samples in methylation/expression batches (run, plate, chip, etc) so that 
batches would not be correlated with intervention and asthma symptoms, thus not likely to be confoundi ng factors. We 
will examine the sensitivity of our result to potential confounding due to cell counts and batch effects. We will use the 
experimentally obtained cell counts and the batch effects estimated by [CONTACT_907024] (SVA)[ADDRESS_1273253] -pre difference in methylation/expression, we will regress out the 
cell count effect and batch effect f irst and then calculate the difference in residual methylation/expression.   
We will repeat the above association analyses by [CONTACT_907021]. 
In the association of intervention with methylation and gen e expression, the interaction term in the model will be 
intervention indicator and sensitization and related phenotypes. For association of asthma symptom and methylation 
and expression, the interaction term in the model will be methylation/expression and sensitization and related 
phenotypes. We will also characterize subjects based on their methylation/expression patterns at baseline before 
intervention. We expect that part of these patterns might reflect epi[INVESTIGATOR_906942],  T H2 or other 
functions measurable in nasal samples . We will examine whether molecular characteristic before intervention modifies 
the size of effect and influences which gene pathways will be changed by [CONTACT_907025].     
Selection of CpGs and genes for technical validation using pyrosequencing and realtime PCR  
We will select representative genes and CpGs in expression/methylation pathway and network. The representative 
genes/CpGs are defined as those that show the most significant individual association with intervention and asthma 
symptom. We will also select t he hub genes/CpGs that show the strongest connection with other genes/CpGs in the 
same pathway and network.  
Relation of mechanistic study design to clinical trial  
Analysis of the data from the mechanistic portion of the study will focus on pathway -specifi c effects of the intervention 
on genome -wide methylation  and expression,  and on the downstream effects of changes in these intermediate 
outcomes on asthma symptoms and other relevant clinical outcomes . In evaluating whether school environment 
exposure abat ement results in molecular changes that modify the course of asthma, we will not only expand our 
understanding of asthma immunopathogenesis, but will also create opportunities to identify potential novel targets for 
asthma phenotype -specific therapy.  
 
13.4.5 Analyses of Exploratory Endpoint (s) 
Exploratory  data  analys is will include compi[INVESTIGATOR_906943], as well as between Filter and 
Control, Groups.  Conti nuous  variables  will be summarized  using means,  medians, standard  deviations,  ranges, and 
interquartile  ranges.  Cont inuous  variables  will be analyzed using  non-parametric  approaches  or will be trans formed  to 
meet  assumptions  of normality required  for parametric  statistics.  Categorical  variables  will be tabulated.  The percent  of 
participan ts who  complete  the study,  losses  to follow -up, missed  visits,  and reasons  for discontin uation will be presented.  
 Confidential  Page [ADDRESS_1273254]  allergen  levels  will be comp ared between the 4  Groups  to assess  efficacy  of allergen  reduction.  
Asthma  symptoms,  rescue medication  use, and health care  utilization  will be compared  between  IPM/Air Filter  and 
Control Groups  to assess  efficacy of the intervention  in reducing  asthma  symptoms  and morbidity.  
Descrip tive statist ics to detect  any outliers or  discrepa ncies in data and to compare  baseline  characteris tics and 
demographics  between IPM  and Education  Groups.  Conti nuous  variables  will be summarized  using means,  medians, 
standard  deviations,  ranges, and interquartile  ranges.  Cont inuous  variables  will be analyzed using  non-parametric  
approach es or will be trans formed  to meet  assumptions  of normality required  for parametric  statistics.  Categorical  
variables  will be tabulated.  The percent  of participan ts who  complete  the study,  losses  to follow -up, missed  visits,  and 
reasons  for discontin uation will be presented.  
13.5  Interim Analyses  (Not Applicable: Environmental Intervention - NOT a medication, high risk 
intervention ) 
13.6  Statistical  Hypotheses  
Clinical Trial Hypothesis and Aims:  Our central hypothesis is that  reducing classroom/school exposure to particles and 
their associated allergens (particularly mouse/mold) will decrease asthma morbidity in students with asthma.  In School 
Inner -City Asthma Intervention Study -2 (SICAS -2) we plan to test our central hypoth esis in an intervention study  of 300 
elementary school -aged children with asthma from multiple classrooms in 40 inner -city elementary schools.  
Aim 1: To determine the effectiveness of a school/classroom based environmental intervention [ Classroom  particle  air 
filter/purifying units and school -wide integrated pest management (IPM)] to:  
 (a)  Reduce asthma symptoms (primary outcome) as used in other NIAID inner -city asthma studies1, 3; 
 (b)  Reduce medication use, health care utilization, and improve lung function (secondary outcomes).  
 
Mechanistic Aims:  
Aim 2:  To test the hypothesis that effects of school/classroom -based environmental interventions on symptoms/other 
measures of asthma control occur through changes in gene methylation or expression in pathways (and secondarily, in 
genes) relevant to airway function and asthma.  Within pathways or networks of genes (pre -specified or discovered in 
unsupervised analyses) we will (a) determine how our interventions influence changes in nasal airway cell methylation 
or gene expression and (b) e valuate how our intervention -associated changes in methylation and gene expression 
influence asthma outcomes.  Finally, using mediation analysis, we will (c) estimate how much of the intervention effects 
on asthma symptoms occurs through methylation/express ion changes1115, 1116. 
Secondary Aim 3:  To ex plore whether sensitization or other asthma phenotypes defined at baseline modify which 
pathways or networks of genes undergo intervention -related changes in methylation or gene expression that, in turn, 
are associated with improvement in asthma outcomes.  
 Confidential  Page 53 of 69 
 
 
 
SICAS -2  Version 3.0  Date 03.27.15   
13.7  Sample Size Considerations Sample Size Estimates:  
 
Power and Sample Size Calculations: (a) Primary Clinical Outcome:  We include the Annual Study Schema Figure 1 
(labeled Figure 5 in the Research Strategy) to aid in understanding both the statistical analysis plan and the power 
calculations. For the primary clinical outcome, assumptions for the sample size estimate for the symptom outcome are 
based on classroom/exposure and symptom data from SICAS -1. The proposed primary statistical analys is assessing the 
impact of the interventions (school - and classroom -based) is based on a multilevel negative binomial regression model, 
which simultaneously accounts for correlation among clustered observations while accounting for over -dispersion in the 
symptom counts We calculated power using a simulation -based approach that repeatedly generated data under this 
model, and calculating the proportion of time we reject the null hypothesis of no school -wide IPM effect (H0: b 3=0) and 
no classroom filter effect  (H0: b 4=0). We assumed θ = 3.  The intercept b 0 = log(3) was chosen to correspond to a rate of 
three symptom days at baseline  prior to the intervention.  The amount of overdispersion in the negative binomial 
distribution was set equal to that estimated in  SICAS -1. Specifically,  this set was using  the overdispersion parameter 
“theta” in the rnegbin function in the MASS package in R.  The random effects standard deviations were set equal to 0.[ADDRESS_1273255] and school random effects, respectively.   All power calculations were run assuming a two -sided 
alpha=0.[ADDRESS_1273256], and all power estimates are based on 1,000 simulated datasets.  Power calc table 2 show s that 
with a total n = 240, we have >80% power to detect a difference of at least 0.6 days  of symptoms and >90% power to 
detect a difference of 0.75 days between the two groups.  Taking into account a conservative projected 20% dropout  
rate (SICAS -1 > 90% retention), we will enroll [ADDRESS_1273257] associations among quintiles of the exposure distribution (as a continuous variable, ), we used the same 
simulation strategy based on a multilevel negative binomial regression model but with exposure quintile as a covariate.  
 
Using this approach, we estimate that we will have 90% power to detect the slope estimated in SICAS -1 of 0.173 ( the 
effect size in Figure 2), which represents the log relative rate per increase in exposure quintile, in as little of [ADDRESS_1273258] exists only in 
subjects sensitized to mouse  and mold (our SICAS -[ADDRESS_1273259] more than 40 sensitized subjects).  
 
Our power calculations for our primary outcome were determined by [CONTACT_907026] -[ADDRESS_1273260] intervention effects on secondary  outcomes, specifically FEV 1 reflecting 
pulmonary function.  We used the same simulation approach outlined above for symptoms, but simulating from a linear  
 Sample Size Estimates: 
Table 2  
Δ sx 
days/2 Total 
N Power:  
IPM Power:  
Class  
 Confidential  Page 54 of 69 
 
 
 
SICAS -2  Version 3.0  Date 03.27.15  mixed effects model for a continuous outcome instead of a negative binomial 
regression model for counts. We used as variance component estimates values 
taken from unpublished analyses of the association between FEV 1 and air 
pollution exposure our group (Gold, Coull, Koutrakis) has just recently 
completed on data from the Childhood Asthma Management Program (CAMP) 
study.  Specifically, from our CAMP analyses using outcome measures taken 
quarterly, we assum ed values of [ADDRESS_1273261] deviation of the outcome, with 0.2 representing a “small” effect size, 0.[ADDRESS_1273262] 80% (90% in parentheses) power to detect an Cohen’s effect size ( for either class or school -wide 
intervention ) of 0.3 (0.4), suggesting we will have the power to detect relatively modest effects of intervention based on 
n=240 after a conservative estimate of 20% dropout (again, we observed <10% dropout in SICAS -1).  Existing published 
results suggest the effect of particle exposures may be at least moderate, with an reported correlation between PM2.5 
and FEV1 of -0.72 (p<0. 01) in Southern [LOCATION_004] public schoolchildren from the Children’s Health Study158.  Therefore 
we are likely to have sufficient power to detect plausible effect sizes of the intervention.  
Analysis will compare IPM versus Control Schools and Air Filter Versus Sham Classrooms, and effi ciently testing the 
effectiveness of the intervention in real life, translatable practicality to all schools, since likely IPM affects school wid e 
exposures, while air filters will affect classroom specific exposures.  The power calculations are based on a  two-sided 
0.[ADDRESS_1273263] information, visits 
consultations, exami nations and other information  are recorded .   Documentation of source data is necessary for the 
reconstruction, evaluation and validation of clinical findings, observations and other activities during a clinical trial.   The 
Data Coordinating Center ( DCC) lead will manage the data repo sitory for the clinical and safety database. She will 
generate reports for review by [CONTACT_907027] a monthly basis or more frequently as dictated by [CONTACT_907028] . 
The investigator  or design ee will to the best of his/her ability encourage compliance in completing case report forms for 
every participant entered into the trial without bein g coercive . In addition, the investigator  or designee  is responsible for 
the reliability of the data  colle cted and recorded in the database  and will  review and sign the pertinent case report weeks  School  
0.60  240 84 89 
280 91 92 
0.75  240 96 98 
280 99 99 
0.90  240 99 100 
280 100 100 
 Confidential  Page 55 of 69 
 
 
 
SICAS -2  Version 3.0  Date 03.27.15  forms, namely adverse events, severe adverse events, and protocol deviations  when completed.   Lung function tests will  
be reviewed and signed by [CONTACT_976] [INVESTIGATOR_261959] ( i.e. certified pulmonology specialist, asthma/allergy specialist).  
Data collected on hard copy forms will be entered into a REDCAP database, which is a  web- based data entry system 
located on the BCH network. It provides audit trails for tracking data changes and user activity as well as automated 
export procedures for seamless downloads to Excel and common statistical packages.  The database has range and valid 
value checks to ensure integrity at the time of data entry. Out of range values must be confi rmed by [CONTACT_907029]. Missing values will be flagged at the time of data entry and reported to the 
project manager for follow -up and resolution. Hard copy source documents will be used to verify missing data o r 
discrepancies whenever available.  
 
The study staff will complete data entry into REDCap as data are collected and at the latest by [CONTACT_907030]. Data will also be 
reviewed on an ongoing  basis and in real time by [CONTACT_907031].   If the Data Manager finds discrepancies or 
missing data, she will assign data queries to the project manager.   It will be the data manager’s  responsibility to check 
the data field against the source doc umentation.   S/he will then respond to the query either by [CONTACT_907032].   If the Data Manager finds the response acceptable, she will make the appropriate 
correction to the database and close the query.   Data queries will be therefore be resolved promptly after identification 
at the time of data entry as well as at monthly intervals during data monitoring and cleaning activities throughout the 
year.  
 
Several procedures will be in place to confirm the completeness, cons istency, and accuracy of all documented data 
within the database(s) for this trial. These include computerized edit checks at the time of data entry and data query 
resolution procedures as described above. In addition, double data entry will be performed o n a randomly selected 
sample of study forms, with the percentage depending on relevance to primary and secondary outcomes. Double data 
entry will be conducted by a second study staff member to evaluate the degree of keying errors and on an ongoing basis 
during data collection. The data manager will run monthly reports comparing the double entry for discrepancies. If any 
errors are found, a query will be opened and directed to the project manager, who will need to return to the source 
documentation to resolv e the issue. The project manager will reply with the correct data that should be captured, make 
the appropriate change, and save the form. The data manager will review changes and close query. Finally, various study 
status and quality reports will also be programmed and generated by [CONTACT_941] D CC to monitor study progress, data integrity, 
and safety. These will include reports that monitor form expectation and completion rates, visit window compliance, 
missing data and out of range values, re cruitment and enrollm ent rates, and withdrawal or loss to follow -up 
rates.  Adverse event reports and Protocol Deviation Reports will also be generated routinely by [CONTACT_906981]. Adverse 
events, protocol deviations study status and data quality reports will be reviewed on an ongoing basis by [CONTACT_978]. In 
addition, these reports will be generated periodically for DSMB  review.  
  
14.2. Access to Source Data  
The site investigators and site staff will make all source data available to the DAIT/NIAID, as well as to relevant health 
authorities .  Authorized representatives as noted above are bound to maintain the strict confidentiality of medical and 
research information that may be linked to identified individuals.  
15. Protocol Deviations  
 Confidential  Page 56 of 69 
 
 
 
SICAS -2  Version 3.0  Date 03.27.15  15.1. Protocol Deviation  Definitions  
Protocol Deviation  – The investigators and site staff will conduct the study in accordance to the protocol; no deviations 
from the protocol are permitted .  Any change, divergence, or departure from the study design or procedures constitutes 
a protocol deviation .  As a result o f any deviation, corrective actions will be developed by [CONTACT_48162].  
 
Major Protocol Deviation (Protocol Violation) - A Protocol Violation is a deviation from the IRB approved protocol that 
may affect the subject's rights, safety, or  well-being and/or the completeness, accuracy and reliability of the study data .  
In addition, protocol violations include willful or knowing breach es of human subject protection regulations, or policies, 
any action that is inconsistent with the NIH Human Research Protection Program’s research, medical, and ethical 
principles , and a serious or continuing noncompliance with federal, state, local or institutional human subject protection 
regulations, policies, or procedures .  
 
Non -Major  Protocol Deviation  - A non-major  protocol deviation is any change, divergence, or departure from the study 
design or procedures of a research protocol that does not  have a major impact on the subject's rights, safety or well -
being, or the completeness, accuracy and reliability of the study data.  
 
15.2. Reporting and Managing Protocol Deviations  
The study site principal investigator  [INVESTIGATOR_393241], document and report protocol deviations  as 
directed by [CONTACT_12925]  (DAIT/NIAID)  .  However, protocol deviations may also be identified during site monitoring 
visits or during other form s of study conduct review.  
Upon determination that a protocol deviation has occurred, the study staff will a) notify the site Principal Investigator, b) 
notify the NIAID Project Mana ger, the DMAC,  and c) will complete a Protocol Deviation form .  The DAIT/NIAID Project 
Manager  will make the decision as to whether the Deviation is major or not  and what the impact of the Deviation on the 
study participant or the entire study may be .  PI [INVESTIGATOR_906944] (IRB, DAIT/NIAID .) and who will review and approve the action plan that will be implemented as a result of the 
Protocol Deviation .  
16. Ethical Considerations and Compliance with Goo d Clinical Practice  
16.1. Statement of Compliance  
This clinical study will be conducted using good clinical practice (GCP), as delineated in Guidance for Industry: E6 Good 
Clinical Practice Consolidated Guidance , and according to the criteria specified in this study protocol.  Before study 
initiation, the protocol and the informed consent documents will be reviewed and approved by [CONTACT_1201].  Any 
amendments to the protocol or to the consent materials will also be approved by [CONTACT_106526].  
The Sponsor (DAIT/NIAID) will review and approve the Protocol and consent documents, and all changes in addition to 
IRB.  
16.2. Informed Consent Process  
 Confidential  Page 57 of 69 
 
 
 
SICAS -2  Version 3.0  Date 03.27.15  The consent process will provide information about the study to a prospective participant and will allow adequate time 
for review and discussion prior to his/her  decision.  The principal investigator [INVESTIGATOR_906945] .  The designees will all be trained in human subjects ’ protect ion 
and conflict of interest and able to provide informed consent per Institution guidelines . The prospective participant will 
be told that being in the trial is voluntary and that he or she may withdraw from the study at any time, for any reason.  
All par ticipants (or their legally acceptable representative) will read, sign, and date a consent form before undergoing 
any study procedures.  Consent materials will be presented in participants’ primary language.  Spanish -speaking 
participan ts will be provided  with  consent  documents  in Spanish  and the consent discussion  will be facilitated  or 
conducted  by a translator.   A copy of the signed consent form will be given to the participant.  
The consent process will be  ongoing .  The consent form will be revised when important new safety information is 
available, the protocol is amended, and/or new information becomes available that may affect participation in the 
study.  
16.3. Privacy and Confidentiality  
A participant’s privacy and confidentiality will be re spected throughout the study.  Each participant will be assigned a 
unique identification number and these numbers rather than names will be used to collect, store, and report participant 
information.  Site personnel will not transmit documents containing p ersonal health identifiers (PHI) to the study 
sponsor  (DAIT/NIAID)  or their representatives.     
17.  Quality  Control and Quality Assurance  
The investigator is required to keep accurate records to ensure that the conduct of the study is fully documented.  The 
investigator is required to ensure that all CRFs are completed for every participant entered in the trial.  Quality Control 
and Quality Assurance processes for data handling are discussed in Section 12.[ADDRESS_1273264] the site prior to the start of the study 
to review with the site staff the protocol, study requirements, and their responsibilities to satisfy regulatory, ethical, an d 
protocol  requirements.  When reviewing data collection procedures, the disc ussion will include identification, 
agreement and documentation of data items for which the CRF  will serve as the source document.  
[COMPANY_003] contracted by [CONTACT_73884]/NIAID will monitor the study to ensure that the:  
 Data are authentic, accurate, and complete.  
 Safety an d rights of subjects are being protected.  
 Study is conducted in accordance with the currently approved protocol and any other study 
agreements, GCP, and all applicable regulatory requirements.  
The investigator agrees to allow the monitor direct access to a ll relevant documents.  
 Confidential  Page [ADDRESS_1273265] a quality assurance 
assessment and/or audit of the site records, and the regulatory agencies may conduct a regulatory inspection at any 
time du ring or after completion of the study. In the event of an assessment, audit or inspection, the investigator (and 
institution) must agree to grant the advisor(s), auditor(s) and inspector(s) direct access to all relevant documents and to 
allocate their time  and the time of their staff to discuss the conduct of the study, any findings/relevant issues and to 
implement any corrective and/or preventative actions to address any findings/issues identified.  
17.1   Data Handling  
The investigator is required to ensur e that all CRFs are completed for every participant entered in the trial.  All elements 
of data entry (i.e., time, date, verbatim text, and the name [CONTACT_8066]) will be recorded 
with an audit trail to allow all data changes in the database to be monitored and maintained in accordance with federal 
regulations.  
 
18. Publication Policy  
Every possible effort will be made for the primary outcome of the trial to be published in a peer -reviewed journal within 
12 months after the database is locked, that DAIT/NIAID will review and comment on any manuscript derived from this 
trial prior to submission and that, if the trial is funded by a NIAID grant of > $500,[ADDRESS_1273266] costs /year, the NIH data 
sharing  policy applies  (http://grants.nih.gov/grants/policy/data_sharing/data_sharing_guidance.htm#goals ) and that 
data from this trial will be shared in accordance to the specific plan that was inc luded in the grant application.     
 
19. References  
1. Morgan WJ, Crain EF, Gruchalla RS, O'Connor GT, Kattan M, Evans R, 3rd, Stout J, Malindzak G, Smartt E, Plaut 
M, Walter M, Vaughn B, Mitchell H. Results of a home -based environmental intervention among urban children with 
asthma. N Engl J Med. 2004;351(11):[ADDRESS_1273267], Kattan M, Kercsmar C, Leickly F, Malveaux F, Smartt  E, Weiss K. Design and methods of the National Cooperative 
Inner -City Asthma Study. Pediatric pulmonology. 1997;24(4):237 -52. 
3. Rosenstreich DL, Eggleston P, Kattan M, Baker D, Slavin RG, Gergen P, Mitchell H, McNiff -Mortimer K, Lynn H, 
Ownby D, Malveaux  F. The role of cockroach allergy and exposure to cockroach allergen in causing morbidity among 
inner -city children with asthma. N Engl J Med. 1997;336(19):[ADDRESS_1273268]. The school inner -city asthma study: design, methods, and lessons learned. J Asthma. 
2011;48(10):1007 -14. PMCID: 3220801.  
5. Wildfire JJ, Gergen PJ, Sorkness CA, Mitchell HE, Calatroni A, Kattan M, Szefler SJ, Teac h SJ, Bloomberg GR, Wood 
RA, Liu AH, Pongracic JA, Chmiel JF, Conroy K, Rivera -Sanchez Y, Busse WW, Morgan WJ. Development and validation of 
the Composite Asthma Severity Index --an outcome measure for use in children and adolescents. The Journal of allergy  
and clinical immunology. 2012;129(3):694 -701. PMCID: 3294274.  
 Confidential  Page [ADDRESS_1273269] KS, Kattan M, Matsui EC, Mitchell H, Sutherland ER, Minnicozzi 
M. Asthma outcomes: symptoms. The Journal of allergy and clinical immunology. 2012;129([ADDRESS_1273270]):S124 -35. 
7. Vital signs: asthma prevalence, disease characteristics, and self -management education: [LOCATION_002], 2001 --
2009. MMWR Morb Mortal Wkly Rep. 2011;60(17):547 -52. 
8. Joseph CL, Foxman B, Leickly FE, Peterson E, Ownby D. Prevale nce of possible undiagnosed asthma and 
associated morbidity among urban schoolchildren. J Pediatr. 1996;129(5):[ADDRESS_1273271] J, Bailey A, King E, Chapman M, Gold D, 
Phipatanakul W. Allergens in urb an schools and homes of children with asthma. Pediatr Allergy Immunol. 
2012;23(6):543 -9. PMCID: 3424376.  
10. Sheehan WJ, Rangsithienchai PA, Muilenberg ML, Rogers CA, Lane JP, Ghaemghami J, Rivard DV, Otsu K, 
Hoffman EB, Israel E, Gold DR, Phipatanakul W. Mouse allergens in urban elementary schools and homes of children 
with asthma. Ann Allergy Asthma Immunol. 2009;102(2):125 -30. PMCID: 2658645.  
11. Permaul P, Petty C, Sheehan W, Baxi S, Gaffin J, Kopel L, Kanchongkittiphan W, Bailey A, Fu C, DR G, Phipatan akul 
W. Mouse Allergen Exposure in Urban Schools and its Effect on Childhood Asthma Morbidity. J Allergy and Clin Immunol. 
2013;131:AB 141.  
12. Baxi S, Petty C, Fu C, Sheehan W, Permaul P, Rogers C, Muilenberg M, DR G, Phipatanakul W. Classroom Fungal 
Spor e Exposure and Asthma Morbidity in Inner -City School Children. J Aller Clin Immunol. 2013;131:AB 54.  
13. Gaffin J, Petty C, Sheehan WJ, Baxi S, Permaul P, Kopel L, Fu C, Kanchongkittiphan W, Gold DR, Phipatanakul W. 
Classroom -Based Air Pollution Effects on  Asthma Morbidity in Inner City School Children. Amer J Respir Crit Care Med. 
2013;187:A2521.  
14. Matsui EC, Eggleston PA, Buckley TJ, Krishnan JA, Breysse PN, Rand CS, Diette GB. Household mouse allergen 
exposure and asthma morbidity in inner -city prescho ol children. Ann Allergy Asthma Immunol. 2006;97(4):[ADDRESS_1273272] of mouse allergen and rodent 
environmental intervention on asthma in inner -city children. Ann Allergy Asthma Immunol. 2008;101(1):35 -41. 
16. Butz AM, Matsui EC, Breysse P, Curtin -Brosnan J, Eggleston P, Diette G, Williams D, Yuan J, Bernert JT, Rand C. A 
randomized trial of air cleaners and a health coach to improve indoor air quality for inner -city children with asthma a nd 
secondhand smoke exposure. Arch Pediatr Adolesc Med. 2011;165(8):741 -8. 
17. Lanphear BP, Hornung RW, Khoury J, Yolton K, Lierl M, Kalkbrenner A. Effects of HEPA air cleaners on 
unscheduled asthma visits and asthma symptoms for children exposed to second hand tobacco smoke. Pediatrics. 
2011;127(1):93 -101. PMCID: 3010094.  
18. Phipatanakul W, Cronin B, Wood RA, Eggleston PA, Shih MC, Song L, Tachdjian R, Oettgen HC. Effect of 
environmental intervention on mouse allergen levels in homes of inner -city [LOCATION_011] c hildren with asthma. Ann Allergy 
Asthma Immunol. 2004;92(4):[ADDRESS_1273273], Phipatanakul W. beta -2 Adrenergic receptor 
gene methylation is associated with decreased asthma severity in inner -city Schoolchildren: Asthma and Rhinitis. Clin 
Exp Allergy. 2014;44(5):[ADDRESS_1273274], Phipatanakul W. Predictors of indoor 
exposure to mouse allergen in inner -city elementary schools. Ann Allergy A sthma Immunol. 2013;111(4):[ADDRESS_1273275], Phipatanakul W. Exposures to molds in school classrooms of children with asthma. Pe diatr Allergy 
Immunol. 2013;24(7):[ADDRESS_1273276], Phipatanakul W. Endotoxin exposure in inner -city schools and homes of children with asthma. Ann All ergy Asthma 
Immunol. 2012;108(6):418 -22. PMCID: 3367391.  
 Confidential  Page [ADDRESS_1273277], Phipatanakul W. Allergens on desktop  surfaces in preschools and 
elementary schools of urban children with asthma. Allergy. 2014;Epub ahead of print.  
24. Baxi SN, Sheehan WJ, Gaffin JM, Yodying J, Panupattanapong S, Lane JP, Fu C, Hoffman EB, Gold DR, 
Phipatanakul W. Agreement between parent and student responses to an asthma and allergy questionnaire in a diverse, 
inner -city elementary school population. Ann Allergy Asthma Immunol. 2011;107(4):371 -3. PMCID: 3187549.  
25. Arbes SJ, Jr., Sever M, Vaughn B, Mehta J, Lynch JT, Mitchell H, Hoppin J A, Spencer HL, Sandler DP, Zeldin DC. 
Feasibility of using subject -collected dust samples in epi[INVESTIGATOR_906946]. 
Environmental health perspectives. 2005;113(6):665 -9. 
26. Curtin -Brosnan J, Paigen B, Hagberg KA, Langley S , O'Neil EA, Krevans M, Eggleston PA, Matsui EC. Occupational 
mouse allergen exposure among non -mouse handlers. J Occup Environ Hyg. 2010;7(12):726 -34. PMCID: PMC3143460.  
27. Platts -Mills TA. Allergen avoidance in the treatment of asthma: problems with the  meta -analyses. The Journal of 
allergy and clinical immunology. 2008;122(4):694 -6. 
28. Ogden CL, Carroll MD, Curtin LR, Lamb MM, Flegal KM. Prevalence of high body mass index in US children and 
adolescents, 2007 -2008. Jama. 2010;303(3):[ADDRESS_1273278] of traffic exposure on children's lung function. American journal of respi[INVESTIGATOR_29424]. 2011;1 84(7):822 -7. PMCID: 3208647.  
30. Curtin -Brosnan J, Paigen B, Hagberg KA, Langley S, O'Neil EA, Krevans M, Eggleston PA, Matsui EC. Occupational 
mouse allergen exposure among non -mouse handlers. J Occup Environ Hyg. 2010;7(12):726 -34. 
31. Pacheco KA. New in sights into laboratory animal exposures and allergic responses. Curr Opin Allergy Clin 
Immunol. 2007;7(2):[ADDRESS_1273279], 
Phipatanakul W. Airborne Fungus Divers ity and Concentrations in Inner City Elementary Schools Ped Aller Immunol. 
2013;24(7):697 -703.  
33. Pongracic JA, O'Connor GT, Muilenberg ML, Vaughn B, Gold DR, Kattan M, Morgan WJ, Gruchalla RS, Smartt E, 
Mitchell HE. Differential effects of outdoor versus  indoor fungal spores on asthma morbidity in inner -city children. The 
Journal of allergy and clinical immunology. 2010;125(3):593 -9. 
34. Lignell U, Meklin T, Putus T, Rintala H, Vepsalainen A, Kalliokoski P, Nevalainen A. Effects of moisture damage 
and ren ovation on microbial conditions and pupi[INVESTIGATOR_8324]' health in two schools --a longitudinal analysis of five years. J Environ 
Monit. 2007;9(3):[ADDRESS_1273280] of source contribution 
uncertainty on the effects of source -specific PM on hospi[INVESTIGATOR_614]: A case study in [LOCATION_011], MA. Journal of exposure 
science & environmental epi[INVESTIGATOR_623]. 2014.  
36. O'Connor GT, Neas L, Vaughn B, Kattan M, Mitchell H, Crain EF, Evans R, 3rd, Gruchalla R, Morgan W, Stout J, 
Adams GK, Lippmann M. Acute respi[INVESTIGATOR_906947]. The 
Journal of allergy and clinical immunology. 2008;121(5):1133 -9 e1.  
37. Brunekreef B, Beelen R, Hoek G, Schouten L, Ba usch -Goldbohm S, Fischer P, Armstrong B, Hughes E, Jerrett M, 
van den Brandt P. Effects of long -term exposure to traffic -related air pollution on respi[INVESTIGATOR_906948]: the NLCS -AIR study. Res Rep Health Eff Inst. 2009 (139):5 -71; discussion [ADDRESS_1273281] J, Bailey A, King E, Chapman M, Gold D, 
Phipatanakul W. Allergens in urban schools and homes of children with asthma. Pediatr Allergy Immunol. 2012.  
39. Fletcher  DJ, Lewis SM, Matthews JN. Factorial designs for crossover clinical trials. Statistics in medicine. 
1990;9(10):1121 -9. 
40. Simon R. Designs for efficient clinical trials. Oncology (Williston Park). 1989;3(7):43 -9; discussion 51 -3. 
 Confidential  Page 61 of 69 
 
 
 
SICAS -2  Version 3.0  Date 03.27.15  41. Niemeijer NR, de Mon chy JG. Age -dependency of sensitization to aero -allergens in asthmatics. Allergy. 
1992;47(4 Pt 2):[ADDRESS_1273282] reactivity to decrements in pulmonary function in children with 
asthma or frequent wheezing. Americ an journal of respi[INVESTIGATOR_4447]. 1995;152(6 Pt 1):2176 -80. 
43. Liccardi G, Cazzola M, D'Amato M, D'Amato G. Pets and cockroaches: two increasing causes of respi[INVESTIGATOR_906949]. Characteristics of airways sensitiza tion and prevention strategies. Respi[INVESTIGATOR_65527]. 
2000;94(11):1109 -18. 
44. Arruda LK, Ferriani VP, Vailes LD, Pomes A, Chapman MD. Cockroach allergens: environmental distribution and 
relationship to disease. Current Allergy and Asthma Reports. 2001;1(5 ):466 -73. 
45. Arshad SH. Indoor allergen exposure in the development of allergy and asthma. Current Allergy and Asthma 
Reports. 2003;3(2):[ADDRESS_1273283]. Distribution a nd 
determinants of mouse allergen exposure in low -income [LOCATION_001] City apartments. Environmental health perspectives. 
2003;111(10):[ADDRESS_1273284] and air in northeastern United 
States inner -city public high schools. Indoor Air. 2005;15(4):228 -34. 
48. Matsui EC, Simons E, Rand C, Butz A, Buckley TJ, Breysse P, Eggleston PA. Airborne mouse allergen in the homes 
of inner -city children with asthma. Journal of Allergy & Clinical Immunolo gy. 2005;115(2):358 -63. 
49. Perry T, Matsui E, Merriman B, Duong T, Eggleston P. The prevalence of rat allergen in inner -city homes and its 
relationship to sensitization and asthma morbidity. Journal of Allergy & Clinical Immunology. 2003;112(2):346 -52. 
50. Phipatanakul W, Eggleston PA, Wright EC, Wood RA, The National Coooperative Inner -City Asthma S. Mouse 
allergen. II. The relationship of mouse allergen exposure to mouse sensitization and asthma morbidity in inner -city 
children with asthma. Journal of Al lergy & Clinical Immunology. 2000;106(6):1075 -80. 
51. Phipatanakul W, Eggleston PA, Wright EC, Wood RA. Mouse allergen. I. The prevalence of mouse allergen in 
inner -city homes. The National Cooperative Inner -City Asthma Study. The Journal of allergy and cl inical immunology. 
2000;106(6):1070 -4. 
52. Phipatanakul W. Rodent allergens. Current Allergy and Asthma Reports. 2002;2(5):[ADDRESS_1273285] Harlem. Journal of Asthma. 2003;40(5):557 -69. 
54. Simoni M, Lombardi E, Berti G, Rusconi F, La Grutta S, Pi[INVESTIGATOR_906950] S, Petronio MG, Galassi C, Forastiere F, Viegi G. 
Mould/dampness exposure at home is associated with respi[INVESTIGATOR_696] d isorders in Italian children and adolescents: the 
SIDRIA -2 Study. Occupational and environmental medicine. 2005;62(9):[ADDRESS_1273286] changes in asthma activity among young adults. Clin Exp Allergy. 2005;35(7):[ADDRESS_1273287] of environmental molds on risk of death from asthma during 
the pollen season. The Journal of allergy and clinical immunology. 1995;95(5 Pt 1):955 -61. 
57. Wallace LA, Mitchell H, O'Connor GT, Neas L, Lippmann M, Kattan M, Koenig J, Stout JW, Vaughn BJ, Wallace D, 
Walter M, Adams K, Liu LJ. Particle concentrations in inner -city homes of children with asthma: th e effect of smoking, 
cooking, and outdoor pollution. Environmental health perspectives. 2003;111(9):1265 -72. PMCID: 1241585.  
58. Delfino RJ, Quintana PJ, Floro J, Gastanaga VM, Samimi BS, Kleinman MT, Liu LJ, Bufalino C, Wu CF, McLaren CE. 
Association of F EV1 in asthmatic children with personal and microenvironmental exposure to airborne particulate 
matter. Environmental health perspectives. 2004;112(8):932 -41. PMCID: 1242025.  
59. Koenig JQ, Mar TF, Allen RW, Jansen K, Lumley T, Sullivan JH, Trenga CA, Lars on T, Liu LJ. Pulmonary effects of 
indoor - and outdoor -generated particles in children with asthma. Environmental health perspectives. 2005;113(4):499 -
503. PMCID: 1278493.  
 Confidential  Page 62 of 69 
 
 
 
SICAS -2  Version 3.0  Date 03.27.15  60. Platts -Mills TA, Vaughan JW, Carter MC, Woodfolk JA. The role of intervention in  established allergy: avoidance 
of indoor allergens in the treatment of chronic allergic disease. Journal of Allergy and Clinical Immunology. 
2000;106(5):[ADDRESS_1273288] mite 
avoidance for children with asthma in homes of low -income families. Journal of Allergy and Clinical Immunology. 
1999;103(6):1069 -74. 
62. Vojta PJ, Randels SP, Stout J, Muilenberg M, Burge HA, Lynn H, Mitchell H, O'Connor GT, Zeldin DC. Effec ts of 
physical interventions on house dust mite allergen levels in carpet, bed, and upholstery dust in low -income, urban 
homes. Environmental health perspectives. 2001;109(8):815 -9. 
63. Gergen PJ, Mortimer KM, Eggleston PA, Rosenstreich D, Mitchell H, Ownb y D, Kattan M, Baker D, Wright EC, 
Slavin R, Malveaux F. Results of the National Cooperative Inner -City Asthma Study (NCICAS) environmental intervention 
to reduce cockroach allergen exposure in inner -city homes. Journal of Allergy and Clinical Immunology. 1999;103(3 Pt 
1):501 -6. 
64. Wood RA. Environmental control in the prevention and treatment of pediatric allergic disease. Current opi[INVESTIGATOR_906951]. 1993;5(6):[ADDRESS_1273289]  mite allergens and the 
clinical activity of asthma. Journal of Allergy & Clinical Immunology. 1996;98(1):[ADDRESS_1273290] GW, Jr., Sporik R, Gelber LE, Chapman MD, Heymann PW. Epi[INVESTIGATOR_906952]. International Archives of Allergy and Applied Immunology. 
1991;94(1 -4):[ADDRESS_1273291] mite from homes of 
atopic asthmatic subjects: a double -blind tri al. Journal of Allergy and Clinical Immunology. 2001;107(1):55 -60. 
68. Phipatanakul W. Animal allergens and their control. Current Allergy and Asthma Reports. 2001;1(5):461 -5. 
69. Phipatanakul W. Environmental indoor allergens. Pediatric Annals. 2003;32(1) :40-8. 
70. Bollinger ME, Eggleston PA, Flanagan E, Wood RA. Cat antigen in homes with and without cats may induce 
allergic symptoms. Journal of Allergy and Clinical Immunology. 1996;97(4):[ADDRESS_1273292] samples. Journal of Allergy and Clinical Immunology. 1989;83(4):[ADDRESS_1273293], Visness CM, Gruchalla RS, Morgan WJ, 
O'Connor GT, Mas tin JP, Mitchell HE. Cost -effectiveness of a home -based environmental intervention for inner -city 
children with asthma. The Journal of allergy and clinical immunology. 2005;116(5):[ADDRESS_1273294] -Katrina New Orleans: The Head -off Environmental Asthma in Louisiana (HEAL) Study. Environment al health 
perspectives. 2012;120(11):1607 -12. 
74. Woods ER, Bhaumik U, Sommer SJ, Ziniel SI, Kessler AJ, Chan E, Wilkinson RB, Sesma MN, Burack AB, Klements 
EM, Queenin LM, Dickerson DU, Nethersole S. Community asthma initiative: evaluation of a quality im provement 
program for comprehensive asthma care. Pediatrics. 2012;129(3):[ADDRESS_1273295] A, Bullen C, Crane J. 
Effects of improved home heating on asthma in community dwelling children: randomised controlled trial. BMJ. 
2008;337:a1411. PMCID: 2658826.  
76. Karlsson AS, Renstrom A, Hedren M, Larsson K. Allergen avo idance does not alter airborne cat allergen levels in 
classrooms. Allergy. 2004;59(6):661 -7. 
 Confidential  Page 63 of 69 
 
 
 
SICAS -2  Version 3.0  Date 03.27.15  77. Karlsson AS, Andersson B, Renstrom A, Svedmyr J, Larsson K, Borres MP. Airborne cat allergen reduction in 
classrooms that use special school clothing or ban pe t ownership. The Journal of allergy and clinical immunology. 
2004;113(6):1172 -7. 
78. Karlsson AS, Renstrom A, Hedren M, Larsson K. Comparison of four allergen -sampling methods in conventional 
and allergy prevention classrooms. Clin Exp Allergy. 2002;32(12) :1776 -81. 
79. Pi[INVESTIGATOR_906953], Nitschke M, Smith BJ, Pi[INVESTIGATOR_906954] D, Ruffin RE, McElroy HJ, Martin J, Hiller JE. Randomized controlled 
trial of unflued gas heater replacement on respi[INVESTIGATOR_906955]. International journal of 
epi[INVESTIGATOR_623] . 2004;33(1):208 -14. 
80. Morales E, Bustamante M, Vilahur N, Escaramis G, Montfort M, de Cid R, Garcia -Esteban R, Torrent M, Estivill X, 
Grimalt JO, Sunyer J. DNA hypomethylation at ALOX12 is associated with persistent wheezing in childhood. American 
journ al of respi[INVESTIGATOR_4447]. 2012;185(9):937 -43. 
81. Baccarelli A, Rusconi F, Bollati V, Catelan D, Accetta G, Hou L, Barbone F, Bertazzi PA, Biggeri A. Nasal cell DNA 
methylation, inflammation, lung function and wheezing in children with asthma. Epi[INVESTIGATOR_241188]. 2012;4(1):91 -100. PMCID: 
3297414.  
82. Woodruff PG, Modrek B, Choy DF, Jia G, Abbas AR, Ellwanger A, Koth LL, Arron JR, Fahy JV. T -helper type 2 -
driven inflammation defines major subphenotypes of asthma. American journal of respi[INVESTIGATOR_4447]. 
2009;180(5):388 -95. PMCID: 2742757.  
83. Woodruff PG, Boushey HA, Dolganov GM, Barker CS, Yang YH, Donnelly S, Ellwanger A, Sidhu SS, Dao -Pi[INVESTIGATOR_906956], 
Pantoja C, Erle DJ, Yamamoto KR, Fahy JV. Genome -wide profiling identifies epi[INVESTIGATOR_906957]. Proc Natl Acad Sci U S A. 2007;104(40):[ZIP_CODE] -63. PMCID: 2000427.  
84. Lambrecht BN, Hammad H. The airway epi[INVESTIGATOR_687799]. Nat Med. 2012;18(5):684 -92. 
85. Poole A, Urbanek C, Eng C, Schageman J, Jacobson S, O'Connor BP, Galanter JM, Gignoux CR, Roth LA, Kumar R, 
Lutz S, Liu AH, Fingerlin TE, Setterquist RA, Burchard EG, Rodriguez -Santana J, Seibold MA. Dissecting childhood asthma 
with nasal transcriptomics distinguis hes subphenotypes of disease. The Journal of allergy and clinical immunology. 
2014;133(3):670 -8 e12.  
86. Baron RM, Kenny DA. The moderator -mediator variable distinction in social psychological research: conceptual, 
strategic, and statistical considerations . Journal of personality and social psychology. 1986;51(6):1173 -82. 
87. Vanderweele TJ, Vansteelandt S. Odds ratios for mediation analysis for a dichotomous outcome. Am J Epi[INVESTIGATOR_5541]. 
2010;172(12):1339 -48. PMCID: 2998205.  
88. Kattan M, Crain EF, Steinbach S,  Visness CM, Walter M, Stout JW, Evans R, 3rd, Smartt E, Gruchalla RS, Morgan 
WJ, O'Connor GT, Mitchell HE. A randomized clinical trial of clinician feedback to improve quality of care for inner -city 
children with asthma. Pediatrics. 2006;117(6):e1095 -103.  
89. Kanabar D, Volans G. Accidental superwarfarin poisoning in children --less treatment is better. Lancet. 
2002;360(9338):963.  
90. Ingels M, Lai C, Tai W, Manning BH, Rangan C, Williams SR, Manoguerra AS, Albertson T, Clark RF. A prospective 
study of acut e, unintentional, pediatric superwarfarin ingestions managed without decontamination. Ann Emerg Med. 
2002;40(1):73 -8. 
91. Position Statement: Allergen Skin Testing. Journal of Allergy and Clinical Immunology. 1993;92:636 -7. 
92. Dweik R, Boggs P, Erzurum S,  Irvin C, Leigh M, Lundberg J, Olin A, Plummer A, Taylor D. An official ATS clinical 
practice guideline: Interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care 
Med. 2011;184(5):602 -15. 
93. NIH.NHLBI. Guideline s for Diagnosis and Management of Asthma: Expert Panel Report 2. 2002:45 -6. 
94. Redline S, Gruchalla RS, Wolf RL, Yawn BP, Cartar L, Gan V, Nelson P, Wollan P. Development and validation of 
school -based asthma and allergy screening questionnaires in a 4 -city study. Ann Allergy Asthma Immunol. 
2004;93(1):36 -48. 
 Confidential  Page 64 of 69 
 
 
 
SICAS -2  Version 3.0  Date 03.27.15  95. Pi[INVESTIGATOR_789810] U, Karlsson G. Methods for obtaining specimens from the nasal mucosa for morphological and 
biochemical analysis. Eur Respir J. 1988;1(9):856 -62. 
96. Stokes A, Kieninger E, Künzi L, Kopf BS , Geiser M, Casaulta C, Regamey N. Comparison of different brushing 
techniques to obtain nasal epi[INVESTIGATOR_906958]. Freitag. 2011.  
97. Lambrecht BN, Hammad H. Asthma: The importance of dysregulated barrier immunity. Eur J Immunol. 
2013;43( 12):[ADDRESS_1273296]. Short -term effects of air 
pollution on oxygen saturation in a cohort of senior adults in Steubenville, Ohio. Journal of occupational and 
environmental medici ne / American College of Occupational and Environmental Medicine. 2014;56(2):149 -54. PMCID: 
3987810.  
99. Wylie BJ, Coull BA, Hamer DH, Singh MP, Jack D, Yeboah -Antwi K, Sabin L, Singh N, MacLeod WB. Impact of 
biomass fuels on pregnancy outcomes in central East India. Environmental health : a global access science source. 
2014;13(1):1. PMCID: 3922846.  
100.  Higgins TS, Reh DD. Environmental pollutants and allergic rhinitis. Curr Opin Otolaryngol Head Neck Surg. 
2012;20(3):209 -14. 
101.  Zhang X, Sebastiani P, L iu G, Schembri F, Dumas YM, Langer EM, Alekseyev Y, O'Connor GT, Brooks DR, Lenburg 
ME, Spi[INVESTIGATOR_20116] A. Similarities and differences between smoking -related gene expression in nasal and bronchial epi[INVESTIGATOR_2130]. 
Physiol Genomics. 2009;41(1):[ADDRESS_1273297]: connections between allergic rhinitis, asthma, and 
chronic sinusitis. Am J Rhinol Allergy. 2012;26(3):[ADDRESS_1273298] MD, Cupp AS, Uzumcu M, Skinner MK. Epi[INVESTIGATOR_906959]. Science. 2005;308(5727):1466 -9. 
104.  Richards E. Inherited epi[INVESTIGATOR_906960] — revisiting soft inheritance. Nat Rev Genet. 2006;7:395 -401.  
105.  Dolinoy DC, Weidman JR, Jirtle RL. Epi[INVESTIGATOR_390250]: Linking early developme ntal environment to adult 
disease. . Reprod Toxicol. 2006.  
106.  Rager JE, Bauer RN, Muller LL, Smeester L, Carson JL, Brighton LE, Fry RC, Jaspers I. DNA methylation in nasal 
epi[INVESTIGATOR_906961]: identification of ULBP3 -related effects. Am J Phys iol Lung Cell Mol Physiol. 
2013;305(6):L432 -8. PMCID: 3763036.  
107.  Beane J, Sebastiani P, Liu G, Brody JS, Lenburg ME, Spi[INVESTIGATOR_20116] A. Reversible and permanent effects of tobacco smoke 
exposure on airway epi[INVESTIGATOR_202281]. Genome Biol. 2007;8(9):R201. P MCID: 2375039.  
108.  Baccarelli A, Wright RO, Bollati V, Tarantini L, Litonjua AA, Suh HH, Zanobetti A, Sparrow D, Vokonas PS, 
Schwartz J. Rapid DNA methylation changes after exposure to traffic particles. American journal of respi[INVESTIGATOR_906962] m edicine. 2009;179(7):572 -8. PMCID: 2720123.  
109.  Bellavia A, Urch B, Speck M, Brook RD, Scott JA, Albetti B, Behbod B, North M, Valeri L, Bertazzi PA, Silverman F, 
Gold D, Baccarelli AA. DNA hypomethylation, ambient particulate matter, and increased blood pressure: findings from 
controlled human exposure experiments. Journal of the American Heart Association. 2013;2(3):e000212.  
110.  Madrigano J, Baccarelli A, Mittleman MA, Sparrow D, Spi[INVESTIGATOR_2152] A, 3rd, Vokonas PS, Cantone L, Kubzansky L, Schwartz 
J. Air pollutio n and DNA methylation: interaction by [CONTACT_907033]. Am J 
Epi[INVESTIGATOR_5541]. 2012;176(3):224 -32. PMCID: 3491965.  
111.  Guo L, By[CONTACT_907034], Zhong J, Motta V, Barupal J, Zheng Y, Dou C, Zhang F, McCracken JP, Diaz A, Marco SG, Coli cino 
S, Schwartz J, Wang S, Hou L, Baccarelli AA. Effects of short -term exposure to inhalable particulate matter on DNA 
methylation of tandem repeats. Environmental and molecular mutagenesis. 2014;55(4):322 -35. 
112.  Hou L, Zhang X, Zheng Y, Wang S, Dou C, Guo L, By[CONTACT_907034], Motta V, McCracken J, Diaz A, Kang CM, Koutrakis P, 
Bertazzi PA, Li J, Schwartz J, Baccarelli AA. Altered methylation in tandem repeat element and elemental component 
levels in inhalable air particles. Environmental and molecular mutagenesi s. 2014;55(3):256 -65. 
 Confidential  Page 65 of 69 
 
 
 
SICAS -2  Version 3.0  Date 03.27.15  113.  Tarantini L, Bonzini M, Apostoli P, Pegoraro V, Bollati V, Marinelli B, Cantone L, Rizzo G, Hou L, Schwartz J, 
Bertazzi PA, Baccarelli A. Effects of particulate matter on genomic DNA methylation content and iNOS promoter 
methylat ion. Environmental health perspectives. 2009;117(2):[ADDRESS_1273299]. Epi[INVESTIGATOR_241188]. 2013; 5(2):147 -54. 
115.  By[CONTACT_907034], Motta V, Panni T, Bertazzi PA, Apostoli P, Hou L, Baccarelli AA. Evolutionary age of repetitive element 
subfamilies and sensitivity of DNA methylation to airborne pollutants. Particle and fibre toxicology. 2013;10:28.  
116.  Tarant ini L, Bonzini M, Tripodi A, Angelici L, Nordio F, Cantone L, Apostoli P, Bertazzi PA, Baccarelli AA. Blood 
hypomethylation of inflammatory genes mediates the effects of metal -rich airborne pollutants on blood coagulation. 
Occupational and environmental me dicine. 2013;70(6):418 -25. 
117.  Peluso M, Bollati V, Munnia A, Srivatanakul P, Jedpi[INVESTIGATOR_906963] A, Sangrajrang S, Pi[INVESTIGATOR_2152] S, Ceppi M, Bertazzi PA, 
Boffetta P, Baccarelli AA. DNA methylation differences in exposed workers and nearby [CONTACT_907035], Rayong, Thailand. International journal of epi[INVESTIGATOR_623]. 2012;41(6):1753 -60; discussion [ADDRESS_1273300] is associated with exhaled nitric oxide in children with asthma. American journal of respi[INVESTIGATOR_116880]. 2011;184(2):191 -7. PMCID: 3172885.  
119.  Verdugo RA, Deschepper CF, Munoz G, Pomp D, Churchill GA. Importance of randomization in microarray 
exper imental designs with Illumina platforms. Nucleic Acids Res. 2009;37(17):5610 -8. PMCID: 2761262.  
120.  Zhang X, Mu W, Zhang W. On the analysis of the illumina 450k array data: probes ambiguously mapped to the 
human genome. Frontiers in genetics. 2012;3:73.  
121. Moen EL, Zhang X, Mu W, Delaney SM, Wing C, McQuade J, Myers J, Godley LA, Dolan ME, Zhang W. Genome -
wide variation of cytosine modifications between European and African populations and the implications for complex 
traits. Genetics. 2013;194(4):987 -96. PMCID: 3730924.  
122.  Du P, Zhang X, Huang CC, Jafari N, Kibbe WA, Hou L, Lin SM. Comparison of Beta -value and M -value methods for 
quantifying methylation levels by [CONTACT_145196]. BMC Bioinformatics. 2010;11:587. PMCID: 3012676.  
123.  Pi[INVESTIGATOR_906964] R, CC Y W, Volta M, Lunnon K, Mill J, Schalkwyk LC. A data -driven approach to preprocessing Illumina 
450K methylation array data. BMC Genomics. 2013;14:293. PMCID: 3769145.  
124.  Hansel NN, Cheadle C, Diette GB, Wright J, Thompson KM, Barnes KC, Georas SN. Analysis  of CD4+ T -cell gene 
expression in allergic subjects using two different microarray platforms. Allergy. 2008;63(3):366 -9. 
125.  Wright RO, Schwartz J, Wright RJ, Bollati V, Tarantini L, Park SK, Hu H, Sparrow D, Vokonas P, Baccarelli A. 
Biomarkers of lead e xposure and DNA methylation within retrotransposons. Environmental health perspectives. 
2010;118(6):790 -5. PMCID: 2898855.  
126.  Hou L, Wang H, Sartori S, Gawron A, Lissowska J, Bollati V, Tarantini L, Zhang FF, Zatonski W, Chow WH, 
Baccarelli A. Blood leuk ocyte DNA hypomethylation and gastric cancer risk in a high -risk Polish population. Int J Cancer. 
2010;127(8):1866 -74. PMCID: 3009461.  
127.  Bollati V, Baccarelli A, Hou L, Bonzini M, Fustinoni S, Cavallo D, By[CONTACT_907034], Jiang J, Marinelli B, Pesatori AC, 
Berta zzi PA, Yang AS. Changes in DNA methylation patterns in subjects exposed to low -dose benzene. Cancer Res. 
2007;67(3):876 -80. PMCID: N.A.  
128.  Bollati V, Schwartz J, Wright R, Litonjua A, Tarantini L, Suh H, Sparrow D, Vokonas P, Baccarelli A. Decline in 
genomic DNA methylation through aging in a cohort of elderly subjects. Mech Ageing Dev. 2009;130(4):234 -9. PMCID: 
2956267.  
129.  Pavanello S, Bollati V, Pesatori AC, Kapka L, Bolognesi C, Bertazzi PA, Baccarelli A. Global and gene -specific 
promoter methylatio n changes are related to anti -B[a]PDE -DNA adduct levels and influence micronuclei levels in 
polycyclic aromatic hydrocarbon -exposed individuals. Int J Cancer. 2009;125(7):1692 -7. PMCID: In Process.  
 Confidential  Page 66 of 69 
 
 
 
SICAS -2  Version 3.0  Date 03.27.15  130.  Rusiecki JA, Baccarelli A, Bollati V, Tarantini L, Mo ore LE, Bonefeld -Jorgensen EC. Global DNA hypomethylation is 
associated with high serum -persistent organic pollutants in Greenlandic Inuit. Environmental health perspectives. 
2008;116(11):1547 -52. PMCID: 2592276.  
131.  Baccarelli A, Wright R, Bollati V, Lit onjua A, Zanobetti A, Tarantini L, Sparrow D, Vokonas P, Schwartz J. Ischemic 
heart disease and stroke in relation to blood DNA methylation. Epi[INVESTIGATOR_623]. 2010;21(6):819 -28. PMCID: In Process.  
132.  Baccarelli A, Tarantini L, Wright RO, Bollati V, Litonjua AA, Zanobetti A, Sparrow D, Vokonas P, Schwartz J. 
Repetitive element DNA methylation and circulating endothelial and inflammation markers in the VA normative aging 
study. Epi[INVESTIGATOR_7009] : official journal of the DNA Methylation Society. 2010;5(3). PMCID: 315 5741.  
133.  Pavanello S, Pesatori AC, Dioni L, Hoxha M, Bollati V, Siwinska E, Mielzynska D, Bolognesi C, Bertazzi PA, 
Baccarelli A. Shorter telomere length in peripheral blood lymphocytes of workers exposed to polycyclic aromatic 
hydrocarbons. Carcinogenes is. 2010;31(2):216 -21. 
134.  Bind MA, Baccarelli A, Zanobetti A, Tarantini L, Suh H, Vokonas P, Schwartz J. Air Pollution and Markers of 
Coagulation, Inflammation, and Endothelial Function: Associations and Epi[CONTACT_37425] -environment Interactions in an Elderly 
Cohort. Epi[INVESTIGATOR_623]. 2012.  
135.  Madrigano J, Baccarelli A, Mittleman MA, Sparrow D, Vokonas PS, Tarantini L, Schwartz J. Aging and epi[INVESTIGATOR_7009]: 
Longitudinal changes in gene -specific DNA methylation. Epi[INVESTIGATOR_7009] : official journal of the DNA Methylation Socie ty. 
2012;7(1).  
136.  Gao Y, Baccarelli A, Shu XO, Ji BT, Yu K, Tarantini L, Yang G, Li HL, Hou L, Rothman N, Zheng W, Gao YT, Chow 
WH. Blood leukocyte Alu and LINE -1 methylation and gastric cancer risk in the Shanghai Women's Health Study. Br J 
Cancer. 2011 . 
137.  Rusiecki JA, Al -Nabhani M, Tarantini L, Chen L, Baccarelli A, Al -Moundhri MS. Global DNA methylation and tumor 
suppressor gene promoter methylation and gastric cancer risk in an Omani Arab population. Epi[INVESTIGATOR_241188]. 
2011;3(4):[ADDRESS_1273301], Gaziano JM, Tucker KL, Baccarelli A, 
Schwartz J, Bollati V, Cassano PA. Folate network genetic variation, plasma homocysteine, and global genomic 
methylation content: a genetic association study. BMC Med Genet. 2011;12(1):150.  
139.  Carugno M, Pesatori AC, Dioni L, Hoxha M, Bollati V, Albetti B, By[CONTACT_907034], Bonzini M, Fustinoni S, Cocco P, Satta 
G, Zucca M, Merlo DF, Cipolla M, Bertazzi PA, Baccarelli A. Increased Mitochondrial DNA Copy Number in Occupatio ns 
Associated with Low -Dose Benzene Exposure. Environmental health perspectives. 2011.  
140.  Bollati V, Galimberti D, Pergoli L, Dalla Valle E, Barretta F, Cortini F, Scarpi[INVESTIGATOR_9384] E, Bertazzi PA, Baccarelli A. DNA 
methylation in repetitive elements and Alzheimer's disease. Brain Behav Immun. 2011;25(6):1078 -83. PMCID: In 
Progress.  
141.  Ursini G, Bollati V, Fazio L, Porcelli A, Iacovelli L, Catalani A, Sinibaldi L, Gelao B, Romano R, Rampi[INVESTIGATOR_8614] A, Taurisano 
P, Mancini M, Di Giorgio A, Popolizio T, Baccarelli  A, De Blasi A, Blasi G, Bertolino A. Stress -Related Methylation of the 
Catechol -O-Methyltransferase Val158 Allele Predicts Human Prefrontal Cognition and Activity. J Neurosci. 
2011;31(18):6692 -8. PMCID: In Process.  
142.  Dioni L, Hoxha M, Nordio F, Bonzini  M, Tarantini L, Albetti B, Savarese A, Schwartz J, Bertazzi PA, Apostoli P, Hou 
L, Baccarelli A. Effects of Short -Term Exposure to Inhalable Particulate Matter on Telomere Length, Telomerase 
Expression and Telomerase Methylation in Steel Workers. Environm ental health perspectives. 2011;119(5):622 -7. 
PMCID: 3094411.  
143.  Fabris S, Bollati V, Agnelli L, Morabito F, Motta V, Cutrona G, Matis S, Grazia Recchia A, Gigliotti V, Gentile M, 
Deliliers GL, Bertazzi PA, Ferrarini M, Neri A, Baccarelli A. Biological a nd clinical relevance of quantitative global 
methylation of repetitive DNA sequences in chronic lymphocytic leukemia. Epi[INVESTIGATOR_7009] : official journal of the DNA 
Methylation Society. 2011;6(2):188 -94. PMCID: In Process.  
144.  Zook PM, Jordan C, Adams B, Visne ss CM, Walter M, Pollenz K, Logan J, Tesson E, Smartt E, Chen A, D'Agostino J, 
Gern JE. Retention strategies and predictors of attrition in an urban pediatric asthma study. Clin Trials. 2010;7(4):[ADDRESS_1273302]  ed. London: Arnold; 2003.  
146.  Fitzmaurice GM LN, Ware JH. Applied Longitudinal Analysis, 2nd Edition. [LOCATION_001]: Wiley; 2011.  
147.  G.M. F, Laird NM, Ware JH, editors. Applied Longitudinal Analysis: Wiley & Sons; 2011.  
148.  Benjamini Y, Hochberg Y. Control ling the false discovery rate: a practical and powerful approach to multiple 
testing. Journal of the Royal Statistical Society, Series B. 1995;57(1):289 -300.  
149.  Hedley AA, Ogden CL, Johnson CL, Carroll MD, Curtin LR, Flegal KM. Prevalence of Overweight a nd Obesity 
Among US Children, Adolescents, and Adults, 1999 -2002. JAMA: The Journal of the American Medical Association. 
2004;291(23):2847 -50. 
150.  Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic acids research. 2000;28(1):27 -30. 
151.  Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, Harris 
MA, Hill DP, Issel -Tarver L, Kasarskis A, Lewis S, Matese JC, Richardson JE, Ringwald M, Rubin GM, Sherlock G. Gene 
ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 2000;25(1):25 -9. 
152.  Harris MA, Clark J, Ireland A, Lomax J, Ashburner M, Foulger R, Eilbeck K, Lewis S, Marshall B, Mungall C, Richter 
J, Rubin GM, Blake JA, Bult C, Dolan M, Drabkin H,  Eppig JT, Hill DP, Ni L, Ringwald M, Balakrishnan R, Cherry JM, Christie 
KR, Costanzo MC, Dwight SS, Engel S, Fisk DG, Hirschman JE, Hong EL, Nash RS, Sethuraman A, Theesfeld CL, Botstein D, 
Dolinski K, Feierbach B, Berardini T, Mundodi S, Rhee SY, Apweil er R, Barrell D, Camon E, Dimmer E, Lee V, Chisholm R, 
Gaudet P, Kibbe W, Kishore R, Schwarz EM, Sternberg P, Gwinn M, Hannick L, Wortman J, Berriman M, Wood V, de la 
Cruz N, Tonellato P, Jaiswal P, Seigfried T, White R. The Gene Ontology (GO) database and  informatics resource. Nucleic 
Acids Res. 2004;32(Database issue):D258 -61. 
153.  Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics. 
2008;9(1):559.  
154.  Poole A, Urbanek C, Eng C, Schageman J, Jacobson  S, O'Connor BP, Galanter JM, Gignoux CR, Roth LA, Kumar R, 
Lutz S, Liu AH, Fingerlin TE, Setterquist RA, Burchard EG, Rodriguez -Santana J, Seibold MA. Dissecting childhood asthma 
with nasal transcriptomics distinguishes subphenotypes of disease. The Journ al of allergy and clinical immunology. 2014.  
155.  Gehlenborg N, O'Donoghue SI, Baliga NS, Goesmann A, Hibbs MA, Kitano H, Kohlbacher O, Neuweger H, 
Schneider R, Tenenbaum D, Gavin AC. Visualization of omics data for systems biology. Nat Methods. 2010;7([ADDRESS_1273303]):S56 -68. 
156.  Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, 
Lander ES, Mesirov JP. Gene set enrichment analysis: a knowledge -based approach for interpreting genome -wide 
expression profiles. Proceedings of the National Academy of Sciences [LOCATION_003]. 2005;102(43):[ADDRESS_1273304]. Am J Hum Genet. 2011;89(1):82 -93. PMCID: 3135811.  
158.  Liu D, Ghosh D, Lin X. Estimation and testing for the effect of a genetic pathway on a disease outcome using 
logistic kernel machine regression via logistic mixed models. BMC Bioinformatics. 2008;9:292. PMCID: 2483287.  
159.  Dittrich MT , Klau GW, Rosenwald A, Dandekar T, Muller T. Identifying functional modules in protein -protein 
interaction networks: an integrated exact approach. Bioinformatics. 2008;24(13):i223 -31. PMCID: 2718639.  
160.  Bind M -A, Vanderweele T, Coull B, Schwartz J. Mixe d effects causal mediation analysis for longitudinal data. 
Submitted to Biostatistics. 2014.  
161.  Liu Y, Aryee MJ, Padyukov L, Fallin MD, Hesselberg E, Runarsson A, Reinius L, Acevedo N, Taub M, Ronninger M, 
Shchetynsky K, Scheynius A, Kere J, Alfredsson L , Klareskog L, Ekstrom TJ, Feinberg AP. Epi[INVESTIGATOR_307999] -wide association data 
implicate DNA methylation as an intermediary of genetic risk in rheumatoid arthritis. Nature biotechnology. 
2013;31(2):142 -7. PMCID: 3598632.  
162.  Cohen J. Statistical Power Analysis f or the Behavioral Sciences. second ed: Lawrence Erlbaum Associates; 1988.  
163.  McConnell R, Islam T, Shankardass K, Jerrett M, Lurmann F, Gilliland F, Gauderman J, Avol E, Kunzli N, Yao L, 
Peters J, Berhane K. Childhood incident asthma and traffic -related air pollution at home and school. Environmental 
health perspectives. 2010;118(7):1021 -6. PMCID: 2920902.  
 Confidential  Page [ADDRESS_1273305]: Oxford University; 2002.  
165.  Benson M, Svensson PA, Carl sson B, Jernas M, Reinholdt J, Cardell LO, Carlsson L. DNA microarrays to study gene 
expression in allergic airways. Clin Exp Allergy. 2002;32(2):301 -8. 
166.  Janssen BG, Godderis L, Pi[INVESTIGATOR_3689] N, Poels K, Kici Ski M, Cuypers A, Fierens F, Penders J, Plusquin M, Gyselaers W, 
Nawrot TS. Placental DNA hypomethylation in association with particulate air pollution in early life. Particle and fibre 
toxicology. 2013;10(1):22. PMCID: 3686623.  
167.  Lilly CM, Tateno H, Oguma T, Israel E, Sonna LA. Effects of allergen ch allenge on airway epi[INVESTIGATOR_906965]. American journal of respi[INVESTIGATOR_4447]. 2005;171(6):579 -86. 
168.  Vittinghoff E, Sen S, McCulloch CE. Sample size calculations for evaluating mediation. Statistics in medicine. 
2009;28(4):541 -57. 
169.  CAMP. Long -term effects of budesonide or nedocromil in children with asthma. The Childhood Asthma 
Management Program Research Group. N Engl J Med. 2000;343(15):1054 -63. 
170.  Asthma prevalence, disease characteristics, and self -manag ement education — [LOCATION_002], 2001 –2009. 
Morbidity and Mortality Weekly Report. 2011;60.  
171.  Gottlieb DJ, Beiser AS, O'Connor GT. Poverty, race, and medication use are correlates of asthma hospi[INVESTIGATOR_214461]. A small area analysis in [LOCATION_011]. Chest. 1995;108(1):28 -35. 
172.  Ungar WJ, editor. Economic Evaluation in Child Health. [LOCATION_001]: Oxford University Press Inc; 2010.  
173.  Akinbami LJ, Sullivan SD, Campbell JD, Grundmeier RW, Hartert TV, Lee TA, Smith RA. Asthma outcomes: 
healthcare utilization and  costs. The Journal of allergy and clinical immunology. 2012;129([ADDRESS_1273306]):S49 -64. 
174.  Paltiel AD, Fuhlbrigge AL, Kitch BT, Liljas B, Weiss ST, Neumann PJ, Kuntz KM. Cost -effectiveness of inhaled 
corticosteroids in adults with mild -to-moderate asthma: resu lts from the asthma policy model. The Journal of allergy and 
clinical immunology. 2001;108(1):39 -46. 
175.  Braithwaite RS, Meltzer DO, King JT, Jr., Leslie D, Roberts MS. What does the value of modern medicine say 
about the $50,000 per quality -adjusted life -year decision rule? Med Care. 2008;46(4):349 -56. 
 Confidential  Page 69 of 69 
 
 
 
SICAS -2  Version 3.0  Date 03.27.15   
 
 
 
 
 
 
 
 
 